|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
REVIEW ARTICLE
From the Northwestern University Medical Center,
Division of Immune Therapy and Autoimmune Disease, Chicago, IL;
Department of Bone Marrow Transplantation & Cancer Immunotherapy,
Hadassah University Hospital, Jerusalem, Israel; Bone Marrow
Transplantation, Medical College of Wisconsin, Milwaukee; Divisione di
Ematologia II, Centro Trapianti di Midollo Osseo, Azienda Ospedaliera
S. Martino, Genoa, Italy.
Hematopoietic stem cells (HSCs) are the earliest cells of the
immune system, giving rise to B and T lymphocytes, monocytes, tissue
macrophages, and dendritic cells. In animal models, adoptive transfer
of HSCs, depending on circumstances, may cause, prevent, or cure
autoimmune diseases. Clinical trials have reported early remission of
otherwise refractory autoimmune disorders after either autologous or
allogeneic hematopoietic stem cell transplantation (HSCT). By
percentage of transplantations performed, autoimmune diseases are the
most rapidly expanding indication for stem cell transplantation.
Although numerous editorials or commentaries have been previously
published, no prior review has focused on the immunology of
transplantation tolerance or development of phase 3 autoimmune HSCT
trials. Results from current trials suggest that mobilization of HSCs,
conditioning regimen, eligibility and exclusion criteria, toxicity,
outcome, source of stem cells, and posttransplantation follow-up need
to be disease specific. HSCT-induced remission of an autoimmune disease
allows for a prospective analysis of events involved in immune
tolerance not available in cross-sectional studies.
(Blood. 2002;99:768-784) Autoimmunity arises from the pathologic reaction of
B-cell-derived antibodies and/or T cells to self-epitopes. Proof of an autoimmune pathogenesis requires adoptive transfer of disease by either
immune cells or antibody.1,2 Transplacental or iatrogenic
transfer of autoreactive antibodies may cause disease. This condition
was first shown in Harrington's self experimentation using plasma from
a patient with idiopathic thrombocytopenic purpura (ITP).3
Mothers with ITP, myasthenia gravis, and/or systemic lupus
erythematosus (SLE) with SSA-Ro-SSB/La immunity may transfer antibodies
to their fetus, resulting in neonatal disease.4-7 Allogeneic stem cell transplantation from donors with autoimmune disease may also transfer the disease to
recipients.8-13
Clinical tolerance is failure of an organism to reject an antigen
or tissue without use of immune-suppressive medications but with intact
normal rejection of third-party or foreign antigens. The oldest theory
of tolerance, and now viewed as orthodoxy, is clonal selection of
lymphocyte repertoires.14 Self-reactive lymphocytes are
deleted and not allowed to mature. Clonal selection as an explanation
for tolerance was first proposed by Burnet15 in 1957 in
regards to antibody formation and self-recognition and
non-self-recognition. Subsequently, this concept was extended to
selection of T cells by deletion of autoreactive clones within the
thymus.16-21 T-cell precursors emigrate from the marrow to the thymus. In the thymus, if self-antigen of sufficient concentration and affinity for their specific T-cell receptor (TCR) repertoires is
present, the T cells undergo apoptosis (deletion) or anergy (functional
silencing).22-25 Because lymphocyte progenitors are continually generated from HSCs, clonal selection would have to be an
ongoing process occurring throughout life.
Thymic editing includes not only negative selection to delete
self-reactive clones but also positive selection to allow maturation of
self-reactive clones.17,26 If a particular TCR fails to engage a major histocompatibility complex (MHC) peptide/complex, or
binds it too tightly, it undergoes apoptosis. If it recognizes an
MHC/peptide complex with moderate avidity, it is positively selected
and undergoes further maturation. The avidity (concentration and
binding affinity) of an MHC/peptide complex appears to play a role in
positive versus negative selection of T lymphocytes.27,28 Intrathymic selection and anergy as a mechanism of maintaining tolerance of autoreactive repertoires was, therefore, amended by
theories concerning peripheral tolerance.29,30
Mechanisms of peripheral tolerance revolve, in part, around the
2-signal hypothesis of self-discrimination and non-self-discrimination introduced by Bretscher and Cohn31 in 1970. T cells,
positively selected within the thymus, remain anergic unless antigen is
presented with a second signal (ie, a costimulatory signal). Basically, antigen presentation to a T cell without costimulation maintains anergy, whereas TCR engagement of antigen combined with costimulation results in T-cell activation.32-35
The traditional costimulatory molecule for T-cell activation is CD28, a
ligand for B7-1 (CD80), and B7-2 (CD86) receptors on T
cells.36 CD28 binding increases transcription of
interleukin 2 (IL-2).35,37 A variety of other molecules,
including CD40L, inducible costimulator (ICOS), and various
adhesion molecules, also provide secondary or tertiary signals to
facilitate T-cell activation.38-43 Requirement of
costimulation for activation may place some constraints on peripheral
sites for cellular activation. Antigen-presenting cells (APCs)
that express costimulatory molecules are localized within secondary
lymphoid tissues (spleen and draining lymph nodes). Transfer of antigen
by immune cells to secondary lymphoid regions may be important to
induce T-cell activation.44 For example, allogeneic tissue
grafts are not rejected in mice that lack secondary lymphoid
tissue.45
Besides the requirement for costimulation, a variety of mechanisms
maintain peripheral tolerance. Some of these mechanisms are similar to
intrathymic tolerance but occur in the periphery, including peripheral
T-cell deletion and/or anergy induced by T-cell interaction with
parenchymal cells.46,47 Other checks to maintain
peripheral tolerance include activation-induced cell death,48 suppressor or regulatory cells,49-51
and peripheral antigen avidity (ie, antigen persistence, concentration,
and affinity).52,53 Theories on peripheral tolerance
explain how a T-cell repertoire selected intrathymically for reactivity
to self maintains peripheral tolerance. A further extension of
tolerance to what has been termed the "danger signal" explains the
context in which costimulation arises.54
The danger metaphor proposed by Matzinger54 involves the
use of the innate immune system (neutrophils, natural killer cells, and
macrophages) to break peripheral tolerance. T-cell-mediated immunity,
known as adaptive immunity, is an evolutionary development of
vertebrates.55 Adaptive immunity involves the
rearrangement of a limited number of germ line genes to produce a
highly diversified repertoire of approximately 1014 to
1018 somatically mutated T-cell (immunoglobulinlike)
receptors and B-cell immunoglobulin receptors. These T cells undergo
deletion and anergy within the thymus. However, the innate immune
system does not have pathogen-receptor repertoire
diversity.56 Response to infection is intrinsic to a
limited number of germ-line receptor genes that recognize
pathogen-specific molecular patterns. These patterns include receptors
for conserved pathogen structures like lipopolysaccharides, mannans,
bacterial DNA, and lipoteichoic acids. Receptor-mediated phagocytosis
of pathogens by macrophages leads to release of proinflammatory
cytokines and expression of costimulation molecules, along with MHC
presentation of pathogen-derived peptides, leading to T-cell
activation. Thus, pathogen stimulation of innate immunity can lead to
activation of the adaptive immune system.57-59
In animal models, active immunization with self-epitopes requires an
adjuvant (immune stimulant) to break tolerance. Adjuvant is often
nothing more than homogenized pathogens such as mycobacterium, which
provides the danger signal for activation of innate APCs such as
macrophages. Presentation of coinjected self-proteins by
adjuvant-activated APCs initiates antigen-specific autoreactive T
cells. Once activated to self by innate immunity, how is the adaptive
immune system prevented from causing autoimmune disease? This question
may be approached by viewing the immune system as dynamic and
constantly fluctuating.
In all prior theories of tolerance, lymphocytes are viewed as
responding or not responding, like a light switch that is on or off.
The perturbation theory postulated by Grossman and Singer60 and Grossman and Paul61,62 proposes that lymphocytes are
dynamically tuned much like a rheostat dims or brightens a room.
Lymphocytes selected intrathymically may maintain a steady tone by
repeated interaction with peripheral tissue. It is the sudden change in dynamic homeostasis that is perceived as a perturbation. By analogy, blood is always dynamically fluctuating between clotting and lysis. In
steady state, blood may be erroneously perceived as static. The immune
system may also be dynamically fluctuating between autoimmunity and
tolerance in a dynamic steady state not readily appreciated. A steady
state that may be controlled by clonal selection, activation, feedback
inhibition, and intracellular receptor and signal transduction tuning.
It is conceivable, but unproven, that immune ablation followed by
infusion of hematopoietic stem cells (HSCs) may "reset the immune rheostat."
All processes involving tolerance, even deletion, are ongoing
recurring events and may be broken. Both central and peripheral T-cell
tolerance may be broken by environmental exposure. Classic agents
capable of breaking tolerance include drugs and
infections.63-65
Drug-induced autoimmunity
Drug-induced disruption of central tolerance implies existence of a
functional thymus throughout adulthood. By using the membrane protein
CD45 to differentiate naive (CD45 RA) from memory (CD45RO) T cells,
thymic-dependent T-cell production appears to diminish markedly after
puberty, presumably because of thymic atrophy. If the thymus involutes,
new adult T cells would then be derived exclusively from peripheral
expansion of existing memory cells. However, with the advent of newer
DNA assays, the accuracy of differentiation between naive and memory T
cells by CD45 has been questioned.73-75
During TCR thymic development, rearrangement of TCR genes leads to
excision of circular DNA termed T-cell receptor rearrangement excision
circles (TRECs).73 TRECs are episomal, unique to T cells,
and do not duplicate during mitosis. Because TCR rearrangement occurs
during thymic development, TRECs may be used as a marker for recent
thymic emigrants. In the early post-hematopoietic stem cell
transplantation (HSCT) period, there is a substantial increase in
peripheral blood TREC-positive T cells.74 Although an
inverse correlation exists between age and TREC production after HSCT, TREC numbers increased in all age groups. Therefore, thymic-dependent generation of T cells occurs in all ages. A drug or
environmental-related disruption of thymic tolerance, which alters TCR
antigen avidity or TCR cytoplasmic or nuclear signaling events, may
allow escape of autoreactive lymphocytes. Once in the periphery,
long-lived autoreactive cells could cause a persistent autoimmune disease.
Infection-induced autoimmunity
An infection could precipitate an autoimmune disease by breaking self-tolerance through molecular mimicry,98,99 determinant or epitope spreading,100,101 or bystander activation.102 Molecular mimicry is the capacity of a lymphocyte activated to an infectious pathogen to cross-react with a similar host determinant. Because memory lymphocytes are long lived, the infectious agent that initiated molecular mimicry to self does not need to persist for autoimmunity to occur. This situation may be one reason for difficulty in proving an infectious etiology for autoimmune disorders. Bystander activation arises when activation of T cells specific for antigen X occurs during an immune response against a nonhomologous antigen Y. In contrast, molecular mimicry is targeted toward self-peptides homologous to the initiating determinant on a viral or other infectious agent. Immunization with adjuvant and peptide is an example of bystander activation to the coinjected nonhomologous peptide.103 Infection-related inflammation is associated with tissue destruction and presentation of self-epitopes, as well as up-regulation of APC costimulatory molecules that may also lead to bystander activation of T cells to self-determinants. Theiler murine encephalomyelitis virus (TMEV)-induced demyelination, an autoimmune demyelinating disease that mimics MS, is an example of viral-induced bystander activation.104 TMEV is a picornavirus (small RNA virus) that infects gray matter neurons but, through bystander activation of the immune system, leads to an autoimmune-demyelinating white matter disease.105 Superantigens may also cause bystander activation. Superantigens are
bacterial, mycoplasma, or viral proteins that activate polyclonal
groups of T cells.106-112 Polyclonal activation arises by
cross-linking the side of a MHC molecule to the V Once molecular mimicry, bystander activation, or superantigens initiate an autoimmune disease, the immune response spreads over time to epitopes that are distinct and non-cross-reactive to the inducing epitope, a phenomenon termed determinant or epitope spreading.113 Epitope spreading has been documented for both T- and B-cell immune responses. A hierarchical order of epitope spreading occurs according to immune dominance of the epitope. Determinant spreading may occur to different regions on the same protein (intramolecular epitope spread) or to a protein distinct from the protein containing the disease-initiating epitope (intermolecular epitope spreading). Temporal spreading of immune responses to other epitopes has been demonstrated in numerous animal autoimmune disorders, including experimental autoimmune encephalomyelitis (EAE),114 diabetes in nonobese diabetic (NOD) mice,115 and experimental autoimmune myasthenia gravis.116 Determinant spreading is suspected to be associated with several human autoimmune diseases, including MS,117 SLE,118 bullous skin diseases,119 myasthenia gravis,120 diabetes,121,122 and chronic rejection of organ allografts.123-125 The mechanism of epitope spreading may be related to costimulation, because in some models blocking CD28/B7 costimulation may prevent epitope spreading.100 Whatever the mechanism, epitope spreading makes it difficult to retrospectively determine the inducing epitope or antigen. Effectiveness of targeted immune interventions directed against one TCR or epitope may be limited by the phenomenon of epitope spreading.
MHC autoimmune-associated genes MHC antigens were initially referred to as tissue transplantation antigens. They were discovered, as the name implies (major histocompatability complex), to have a major role in rejection of transplanted organs. As later discovered by Zinkernagel and Doherty,126 the MHCs are peptide-presenting molecules resulting in MHC/peptide restriction for T-cell recognition.127 It is not, therefore, surprising that many autoimmune diseases are associated with particular MHC genotypes.Numerous suspected autoimmune disorders (such as MS, RA, spondyloarthropathies, diabetes, myasthenia gravis, Crohn disease, primary biliary cirrhosis, autoimmune hepatitis, SLE, vasculitis, pemphigus vulgaris, and Sjögren syndrome) are associated with MHC alleles.128 Because combined MHC/peptide presentation is essential for T-cell activation, a MHC association may be indirect evidence for an immune pathogenesis. RA-prone MHC alleles, their frequencies vary for different ethnic groups, share a similar amino acid epitope sequence (LLEQKRAA or LLEQRRAA) encoded by codons 67 to 74.129-131 The HLA sequence 67 to 74 is a HLA contact site for both peptide and TCR binding. This finding suggests HLA presentation of a common infectious or self-antigen to T cells is involved in the pathogenesis of RA. Spondyloarthropathies are linked with only some molecular subtypes of HLA-B27.132 Similar to RA, peptide-binding differences may explain differences in disease susceptibility. HLA-B27 may even present its own B27-derived peptides. In which case, the putative arthritogenic peptide may be a component of the HLA-B27 molecule. The autoimmune etiology for scleroderma is questionable because of poor response to immune suppressive medications. Similarly, scleroderma also has a relatively weak MHC association that may indicate only partial immune pathogenesis or weak linkage of scleroderma genes to MHC alleles or the absence of an autoimmune etiology.133 Although MHC genes correlate with autoimmune disease susceptibility, most patients with disease-associated MHC genes remain disease free throughout their lifespan. Environment and/or non-MHC genes must, therefore, contribute toward development of disease. Non-MHC autoimmune genes Multiple non-MHC genes that regulate cell proliferation (oncogenes), cell signaling (tyrosinases), immune response (costimulatory molecules, interleukins, and cytokines), and apoptosis (fas) may play a role in development of autoimmunity.134 Analysis of the diabetic-prone NOD mouse has revealed at least 18 insulin-dependent diabetes prone genes.135 SLE occurs in various strains of mice, including Murthy Roth lymphoproliferative (MRL/lpr) mice and New Zealand Black X New Zealand White F1 hybrid (NZB/NZW) mice.136 Various mating crosses of lupus-prone mice, as well as backcrosses to normal mice, have linked murine lupus to 38 different genomic loci.137 Some loci are associated with glomerulonephritis, others with vasculitis, some with anti-ds DNA, some with antichromatin antibody, some with lymphoproliferation, and others with splenomegaly. No single gene is sufficient to cause disease. Various combinations of SLE-prone genes among different patients may explain why patients with SLE can have highly variable organ involvement and clinical symptoms. Collagen-induced arthritis in rats is a model for RA and is induced by injection of collagen and adjuvant.138,139 At least 14 genomic intervals or collagen-induced arthritis (CIA) loci are associated with collagen-induced arthritis.140,141Although autoimmunity involves MHC and numerous non-MHC genes, environmental interactions with these genes are essential to manifest disease. Approximately two thirds of syngeneic twins with MS, RA, SLE, or type I diabetes are discordant for clinical disease.142 Although a concordance rate of 33% is much higher than the general population, it remains significantly below a predetermined dominant Mendelian penetrance of 100% and suggests that environmental factors continue to have a significant role in polygenic autoimmune diseases.
Animal models and anecdotal case reports Animal autoimmune diseases that are induced by immunization with adjuvant or self-peptide and adjuvant may be ameliorated by syngeneic or pseudo-autologous HSCT.143-155Immunization with adjuvant and either myelin basic protein or proteolipid protein peptides induces a T-cell-mediated demyelinating disease, EAE, that, depending on the animal model, may be monophasic, relapsing-remitting with secondary progression, or progressive from onset. EAE in Swiss Jackson Laboratory/Jackson (SJL/J) mice is a relapsing, remitting, and secondarily progressive disease. Several investigators have demonstrated cure, decreased relapse rates, or decreased disease severity in EAE animals undergoing syngeneic HSCT.146,149-151 Because of the expense of long-term animal housing, most experiments in EAE are performed before disease onset to abort disease initiation or shortly after disease onset to ameliorate its course. It is unlikely that such experiments are applicable to patients with a long duration of MS with accumulated disease burden and tissue damage. Syngeneic HSCT performed in mice with chronic EAE, unlike the results in acute EAE, failed to demonstrate neurologic improvement.146 Histologic analysis revealed chronic scarring with glial proliferation that is unaffected by HSCT.146 To be effective as therapy for EAE, HSCT needs to be performed early in the disease course during its inflammatory stage and before accumulation of disease burden. A principle that may also be important for MS. Murine bone marrow transplantations are performed by killing and removing the femur from the donor and using a syringe to flush out the marrow cells. It is technically difficult and inhumane to perform a murine autologous transplantation because the surviving recipient's legs would have to be amputated. However, marrow could be harvested from a syngeneic donor in the same active stage of EAE as the recipient, referred to as a pseudoautologous transplant. HSCT of EAE using pseudoautologous donors suggests that infused lymphocytes contaminating the graft may contribute to relapse.147 This suggestion indicates that lymphocyte depletion of grafts may be important in decreasing posttransplantation relapse after autologous HSCT. Besides immunization with myelin peptides, demyelinating central nervous system disease may be induced with viruses such as TMEV.156 Autologous HSCT of TMEV-induced demyelinating disease causes a high mortality from viral superinfection of the central nervous system during the postconditioning pancytopenic period.156 Autoimmune disease mediated by an infectious agent can be rapidly fatal after autologous HSCT but only if the infectious agent is still present at the time of transplantation. Several other environmentally induced animal autoimmune diseases are improved or cured by syngeneic HSCT. These diseases include experimental autoimmune myasthenia gravis,153 adjuvant arthritis 154,155 and collagen-induced arthritis.145 Encouraging results of syngeneic and pseudoautologous HSCT in animal-induced autoimmunity supported the design of autologous and syngeneic HSCT trials in patients with severe autoimmune disorders. Anecdotal case reports of patients with a coincidental autoimmune disease and a malignancy provided further support and rationale for trial design.157-166 Refractory autoimmune diseases entered remission sometimes for several years. Because the indication for transplantation was a malignancy, and the outcome was reported retrospectively, in most cases a detailed pretransplantation evaluation by a rheumatologist or neurologist is missing. The autografts were usually not purged of lymphocytes, and the transplantations were not tailored as therapy for an autoimmune disease. Duration of response appeared shorter for RA compared with SLE. Too few patients have been reported for other autoimmune diseases, and long-term results of response to treatment in those that relapse, as well as duration of remission in those who had not relapsed, remain unknown. Mobilization of HSCs Collection of stem cells from patients with autoimmune diseases is based on methods already established for patients with nonautoimmune disorders. The complications and risks of the procedure appear greater in patients with autoimmune disease and are specific for the autoimmune disease and involved organ system.167 The most common peripheral blood stem cell (PBSC) mobilization regimens are single-agent granulocyte colony-stimulating factor (G-CSF) or cyclophosphamide and G-CSF.Flares of MS and RA have occurred while patients were taking G-CSF for mobilization.167,168 MS flares have resulted in serious and irreversible neurologic deterioration. G-CSF-related flares of RA are relatively mild, being manifest as a transient increase in the number of swollen or tender joints that resolves with or without an increase in corticosteroid dose.167 The only complications of G-CSF PBSC mobilization in patients with scleroderma are transient telangiectasia that spontaneously resolves.167 In other diseases, such as SLE, there exists virtually no data on PBSC with G-CSF as a single agent. The simultaneous administration of G-CSF and steroids has been used in a limited number of patients without disease exacerbation.169 To prevent G-CSF-related disease flare, combined cyclophosphamide and G-CSF (Cy/G-CSF) may be used for mobilization. However, combined Cy/G-CSF PBSC mobilization has been complicated by neutropenic-related infection and disease-specific fatal visceral organ toxicity.167 Infections with opportunistic organisms may be more common in patients who have been on high-dose corticosteroids for prolonged intervals, such as patients with refractory SLE. Scleroderma patients with cardiac and/or pulmonary involvement undergoing PBSC with 4.0 g/m2 cyclophosphamide have succumbed to cardiac arrest and/or pulmonary alveolar hemorrhage.167 No significant regimen-related organ damage has been reported at doses of 2.0 g/m2 or for doses of 4.0 g/m2 in nonscleroderma patients. This finding emphasizes the importance of adjusting the mobilization regimen based on disease and organ involvement for the minimum mobilization-related morbidity. Although cyclophosphamide-based mobilization is generally associated with more toxicity from infection or organ damage, autoimmune diseases are generally ameliorated by the immune suppressive effects of cyclophosphamide.167 The duration of improvement from cyclophosphamide-based PBSC mobilization is unknown because most patients proceed within a relatively short time interval from mobilization to HSCT. As an exception, in at least one autoimmune disease (Evans syndrome), cyclophosphamide-based PBSC resulted in rapid and fatal acceleration of disease activity.170 This acceleration was attributed to a rapid cyclophosphamide-induced suppression of otherwise compensatory and accelerated hematopoiesis in the presence of persistent peripheral destruction from residual immunoglobulins against red blood cells and platelets. There is no single optimal mobilization regimen for PBSC in patients with autoimmune disease. The PBSC method should be individualized for the disease and organ system involved. Newer mobilizing agents such as stem cell factor, thrombopoietin, chemokines, and/or high-dose corticosteroids and G-CSF need to be evaluated to collect progenitor stem cells with minimum mobilization-related morbidity. After collection of progenitor cells, most but not all centers perform ex vivo lymphocyte depletion.167 Because the existence or identity of suppressor cells remains vague, graft depletion techniques are nonspecific without attempts at conserving regulatory cells. Positive enrichment for CD34+ cells has been performed by using either CEPRATE (CellPro, Bothel, WA), Isolex (Nexel, Irvine, CA), or CliniMACS (Miltenyi, Bergish Gladbach, Germany) cell separation systems. Negative selection was performed with T-cell antibodies by e-rosette or Nexel Isolex CD4/CD8 selection. Insufficient clinical data are currently available to compare an unmanipulated versus a T-cell-depleted graft in terms of disease response or relapse. Aggressive lymphocyte depletion may adversely affect immune reconstitution against pathogens, increasing the risk of serious posttransplantation opportunistic infections such as cytomegalovirus, fungemia, Pneumocystis carinii pneumonia, or Epstein-Barr virus posttransplantation lymphoproliferative disease (PTLD). Conditioning regimens and the role of immunosuppressive versus myeloablative conditioning for reinduction of self-tolerance The first convincing evidence that intense immunosuppression may cure life-threatening autoimmune diseases was obtained in a patient with mixed cryoglobulinemia in end-stage renal failure with a cryocrit level of 60%.171 In the early 1970s, a patient with monoclonal immunoglobulin (Ig)M and polyclonal IgG was treated with a combination of cyclophosphamide and azathioprine. Treatment was complicated by lymphocytopenia and sepsis because of neutropenia, but the patient recovered with no stem cell support. After recovery, renal function normalized in parallel with elimination of the cryoglobulinemia, and the patient is alive and disease free for more than 25 years.171 This case represents the longest observation of a patient with reinduced self-tolerance after elimination of self-reactive lymphocytes and reestablishment of immunity from uncommitted stem cells.Brodsky et al172 extended this early observation by treating a variety of autoimmune diseases with high-dose cyclophosphamide (200 mg/kg) without HSC infusion.172 For some autoimmune diseases such as SLE, early results from high-dose cyclophosphamide without stem cell support are encouraging. Although the response rate is high, depending on disease, relapse is common. With the exception of some diseases such as SLE, a more intense and myeloablative regimen with stem cell support may be required for durable responses. Infusion of mobilized HSCs shortens the duration of neutropenia by 5 to 7 days, theoretically decreasing the risk of serious infections. Ex vivo expansion of HSCs before infusion may completely eliminate neutropenic-related infections. For these reasons, a trial that randomized between cyclophosphamide with or without stem cell support is not currently being planned, and the rest of this review will be devoted to immune suppression with HSC support. Ideally, the conditioning regimen should be able to eliminate immune cells without neutropenia. Such a regimen does not exist. The more immune ablative a regimen becomes, the more likely it is to be myeloablative and require stem cell support for reconstituting hematopoiesis. The conditioning regimens being used in autoimmune transplantations were empirically developed for use in malignancies. Autoimmune conditioning regimens include cyclophosphamide (Cy)173-177; cyclophosphamide and polyclonal antilymphocyte antibodies such as antithymocyte globulin (ATG) or humanized monoclonal rat antihuman CD52 (Campath-1H) antibodies (Cy/ATG or Cy/Campath-1H, respectively)178-188; carmustine, etoposide, cytarabine, and melphalan (BEAM) 189-192; cyclophosphamide and total body irradiation (Cy/TBI)193; cyclophosphamide, TBI, and antithymocyte globulin (Cy/TBI/ATG)194,195; busulfan and cyclophosphamide (Bu/Cy)196,197; busulfan, cyclophosphamide, and ATG (Bu/Cy/ATG)198; cyclophosphamide and thiotepa (Cy/TT)199,200; and fludarabine-based regimens. Cy or Cy/ATG is the most common conditioning regimen used for HSCT of SLE.181-184,188 Pulse cyclophosphamide (500-1000 mg/m2) is a standard treatment for SLE. It is, therefore, reasonable to escalate cyclophosphamide to transplantation doses as the conditioning regimen for SLE. To avoid cardiac injury, transplantation doses of cyclophosphamide are limited to 200 mg/kg usually divided into 50 mg/kg per day. Cyclophosphamide is often used to mobilize stem cells before HSCT at doses of 2.0 to 4.0 g/m2. If cyclophosphamide is used in both the mobilizing and conditioning regimen, either the conditioning regimen dose may be decreased or the time interval between mobilization and HSCT may be delayed by several weeks to minimize the risk of cardiac toxicity from total cyclophosphamide dose. When the conditioning dose of cyclophosphamide is decreased, some centers add another agent such as thiotepa.199,200 Most patients with SLE eligible for HSCT are corticosteroid dependent and markedly cushingoid. There is a marked discrepancy between ideal and actual weight in terms of calculating cyclophosphamide dose. For safety reasons, in cushingoid patients, the dose is generally based on ideal or an adjusted ideal rather than actual weight. Cy and Cy/ATG are conditioning regimens for scleroderma176,187,188 and RA.173-175,180 High-dose cyclophosphamide may be associated with high cardiopulmonary mortality in patients with scleroderma.167 Volume shifts and infections that stress cardiovascular reserve are the likely culprit of HSCT-related cardiopulmonary collapse in scleroderma-associated pulmonary artery hypertension. In RA, organ function is generally normal, and cyclophosphamide-related toxicity is less problematic. The toxicity of a conditioning regimen, therefore, depends on the disease and disease-related organ dysfunction. Bu/Cy regimens have been used in a limited number of HSCTs for MS197 and RA.196 Busulfan is fat soluble and readily crosses the blood-brain barrier to the site of MS plaques. Busulfan is administered orally with variability in absorption and first-pass hepatic metabolism. Busulfex is an intravenous formulation that gives more uniform and less toxic serum levels. For RA, it may be equally important for efficacy that the conditioning regimen target not only lymphocytes but also synovial macrophages. Theoretically, HSCT results may be improved in RA by adding a more effective antimacrophage agent such as busulfan to a cyclophosphamide-based regimen.201 There are special concerns about the use of Bu/Cy in RA and MS. Patients with RA may have disease-related interstitial pneumonitis with little reserve for busulfan-related lung injury. The effects of alkylating agents on demyelinated neurons are unknown. In MS, the neurotoxicity of high-dose alkylating-based conditioning regimens remains unknown. BEAM and Cy/TBI are common lymphoma regimens being used to treat MS.189-191,193 TBI was selected because, unlike most agents, radiation readily crosses the blood-brain barrier. To avoid TBI-related pulmonary injury, radiation is generally given in the anteroposterior and posteroanterior position with 50% lung blocks with full dose to the mediastinal lymph nodes and spinal cord. A comparison of BEAM versus Cy/TBI regimen-related toxicity has not been performed. In general, TBI regimens are not used in RA because trials of nonmyeloablative total nodal irradiation in RA were associated with unexpected late complications such as myelodysplasia.202 Cy/TBI/ATG has been used as a conditioning regimen in the United States for scleroderma195 and MS,169 and in Europe for juvenile chronic arthritis (JCA).194 For patients with pulmonary scleroderma, TBI without lung shielding has been associated with lethal pulmonary deterioration.195 If attenuated with partial lung shields, TBI-related scleroderma lung injury appears less likely. Cy/TBI/ATG has been associated with lethal PTLD.358 The investigators attributed PTLD to use of high-dose rabbit ATG. Lower and less immune-suppressive doses of rabbit ATG or the use of horse ATG has not been reported to cause PTLD in autoimmune diseases. Independent of the conditioning regimen (Cy or Cy/TBI/ATG), when combined with aggressive T-cell depletion, HSCT in JCA has been complicated by lethal macrophage activation syndrome (MAS), manifesting as fever, lymphadenopathy, hepatosplenomegaly, and disseminated intravascular coagulation.186 MAS is a reactive hematophagocytic lymphohistiocytosis and has been associated with JCA independent of HSCT.203 The diagnosis is confirmed on bone marrow aspirate by macrophages (or histiocytes) actively phagocytosing hematopoietic cells and may arise from immune dysregulation perhaps in response to viral infections. To date, posttransplantation MAS appears to be a complication unique to JCA. No reports exist of late regimen-related organ toxicity from HSCT in autoimmune diseases. All patients need to be warned of infertility and of regimen-specific late toxicities such as cataracts from TBI. Late malignancies are also possible.204 Similar to mobilization regimens, conditioning regimens must be uniquely designed for the disease, organ impairment, disease-specific infection susceptibility, and extent of prior immune suppressive medication-related infectious risk to ensure minimum regimen-related mortality. Mortality Transplantation-related mortality (TRM) for all autoimmune diseases has been reported to be 8.6%.205 TRM is disease specific, in order of highest to lowest TRM: scleroderma, SLE, MS, and RA. This mortality is higher than expected because of phase 1 trials that selected patients with advanced end-organ dysfunction and/or active and refractory disease. Judicious selection of patients earlier in disease or in remission, but with a high risk of relapse or further progression, will diminish TRM. Variability in TRM based on the center performing the transplant, also known as the center effect,206 may be occurring for autoimmune diseases. Many factors affect TRM, including patient selection, supportive care, conditioning regimen, degree of lymphocyte depletion of the graft, use of disease-specific versus generic protocols, and so forth. A lower mortality in centers dedicated to autoimmune HSCTs may be obscured within the variability of multicenter registry data.Posttransplantation immunization After HSCT, a patient's titer from prior immunizations (eg, diphtheria, measles, tetanus, hepatitis B, etc) is often low or undetectable. As discussed in the "Breaking tolerance by environmental exposure" section, immunization could, theoretically, reinduce autoimmune disease. The risk of relapse may vary according to the type of immunization. For example, there was concern that onset and flare of MS may be associated with hepatitis B vaccination, although recent studies have shown no association.207 Although the risk of infection-related mortality or infection-induced autoimmunity in a nonimmunized individual probably outweighs any theoretical risk of immunization-induced disease relapse, guidelines on posttransplantation vaccination in autoimmunity have yet to be written.
MS, SLE, RA, and scleroderma will be discussed further because phase 3 autologous HSCT trials are being prepared in these diseases. In Europe, the European Bone Marrow Transplant/European League Against Rheumatism (EBMT/EULAR) autoimmune committee is designing these trials. In the United States, the trials are funded by the National Institutes of Health and are being designed by disease-specific working groups composed of transplant physicians, rheumatologists, and neurologists. Autologous HSCT for MS MS is a relatively common North American and European disease with a prevalence of approximately 1 in 1000 people.208 It is at onset an immune-mediated disease confined to the central nervous system. The disease is characterized by a variable course.209-211 Patterns are (1) relapsing-remitting MS defined as relapsing disease without progression between relapses with or without residual neurologic deficits from each relapse, (2) secondary progressive MS defined as continuous (often insidious and steady) neurologic deterioration with or without superimposed relapses after an initial relapsing-remitting course, and (3) primary progressive MS defined as steady continuous deterioration from onset. At onset, approximately 15% of the cases are primary progressive and 85% are relapsing-remitting.209-211 Within 10 years, 50% of relapsing-remitting cases become secondary progressive, and by 25 years, 90% have progressive disease. Relapse frequency in the first year of diagnosis influences time interval to disability.209-211 The median time to difficulty ambulating without unilateral assistance (an extended disability status score [EDSS] of 6.0) is 7 years for 5 or more relapses; 13 years for 2 to 4 relapses; and 18 years for 1 to 2 relapses.Accepted immune-modulating agents for MS are interferon beta (Avonex,
Betaseron)212-216 or Copaxone (copolymer 1 or glatiramar acetate)217,218 known as ABC therapy. Avonex and Betaseron
are different formulations of interferon- Natural history magnetic resonance imaging (MRI) studies have demonstrated that neurologic progression can continue despite lack of new demyelinating events on MRI.222,223 Although early relapse frequency within the first year of diagnosis appears to correlate with onset of late disability, Confavreux et al224 reported that relapse frequency in disease of longer duration and EDSS scores more than 4.0 do not correlate with disability. This finding indicates that treatment designed to prevent relapses (ie, immune-modulating therapy) used late in disease is probably not adequate to prevent progressive disability. Demyelination alone does not adequately explain the progressive disability that occurs in patients with progressive MS. Yet, the most important therapeutic goal is to prevent disability and maintain neurologic function. An evolving amount of literature on MS supports the concept that, although initially an inflammatory demyelinating disease, MS transitions into or is also an axonal degenerative disease.225-228 HSCT for MS was suggested in 1995.229 In general, initial
HSCTs were phase 1 studies and captured patients with progressive disease and high disability (EDSS) scores189-191,230-233
(Table 1). The Thessaloniki group
has reported a 3-year progression-free survival for primary progressive
MS (39%), which appears significantly lower than for secondary
progressive (92%).190 In an Italian study, Mancardi et
al231 reported 10 subjects undergoing HSCT followed with a
frequent MRI protocol who demonstrated lack of enhancing lesions and
accumulation of T2 burden of disease over an observation period of 4 to
30 months. A second study with a 5-year follow-up has noted a
discordant response between MRI and clinical results.230
Some patients had clinical progression of disability, defined as an
increase in the EDSS by one or more points but no new attacks or change
on MRI in terms of T2 disease burden. The patients whose EDSS increased
despite lack of MRI changes had significant pretransplantation
disabilities (EDSS of 7.0 to 8.5). Although longer follow-up is
necessary, it appears that HSCT slows or halts acute attacks and
further immune-mediated demyelination but not progressive disability,
especially in disease of increasing duration or higher disability
scores.
Two possible phase 3 MS trial designs are being proposed to run simultaneously. For secondary progressive MS, the trial would be aimed at suppressing relapses in patients with progressive disability. Patients with accumulated baseline deficits, but still inflammatory disease, could be considered candidates. This group could include ambulatory patients with an EDSS of 3.5 to 6.0 and continued relapses (or MRI evidence of active disease) randomized between a TBI and Cy regimen with or without low-dose ATG and CD34-selected HSCs versus mitoxantrone every 3 months for 2 years. However, suppression of relapses may be insufficient to halt progressive neurologic impairment, particularly as the duration of disease and the level of disability increase. For relapsing-remitting MS, the protocol would be aimed at suppressing relapses in patients at risk for progressive disability. Patients with relapsing-remitting disease who have failed interferon may be randomized between cyclophosphamide (200 mg/kg, with or without low-dose ATG) with CD34-selected HSC support versus best standard therapy (ie, continued interferon or interferon and adjuvant immunotherapy) (azathioprine, methotrexate, mitoxantrone, or cyclophosphamide). Because patients in this study would be earlier in the disease course, a safer conditioning regimen that does not include TBI would be indicated. Efficacy of earlier intervention in MS is supported by the Controlled High-risk Subjects Avenox Multiple Sclerosis Prevention Study (CHAMPS), in which over a 3-year interval treatment with interferon after the first clinical event significantly lowered the probability of developing clinically definite MS.234 If early intervention before onset of progressive disease is important in preventing late disability, a safe but intense immune suppressive regimen might be indicated in patients with relapsing-remitting MS who have failed interferon. Although the primary outcome of these trials would be progressive disability defined by the EDSS, other outcome measures would include clinical status by the Neurologic Rating Scale and Multiple Sclerosis Functional Composite, measurement of accumulated atrophy on MRI of the brain and cervical spinal cord, and potentially measures of whole brain N-acetyl-aspartate on magnetic resonance spectroscopy that reflects neuronal and axonal integrity. Autologous HSCT for SLE Although studies have suggested that SLE encompasses several genetic diseases with some clinical commonalties,235,236 the disease will be considered here as a single entity with protean clinical expressivity.237,238 SLE has an overall prevalence that has varied from 12 to 50.8 cases per 100 000 persons.239 Survival has improved dramatically, reaching a 90% 10-year survival and a 70% 20-year survival in the 1990s. Within the first 5 years, the main cause of death is active disease (neurologic, renal, systemic) or infection. Thereafter, causes of death tend to be infectious or cardiovascular events (strokes and/or myocardial infarction) related to hypertension and hyperglycemia/hypercholesterinemia because of chronic corticotherapy.Three consecutive but separable levels of etiology, ethiopathogenesis, and pathogenesis have been considered for SLE.240 It has been thought imperative to identify the specific molecular defects as the only way to design and use any novel and rational treatments.241 In practice, however, SLE is treated with a variety of drugs, mainly immunosuppressive, that have been discussed recently.242 Along with corticosteroids, intravenous pulse cyclophosphamide has been used in a National Institutes of Health-developed protocol specifically directed toward lupus nephropathy.243 At the pinnacle of the lupus iceberg, however, there are cases of refractory-relapsing ("intractable")244 disease. For such patients, following the considerable experimental evidence discussed formerly and also on the basis of serendipitous case reports of coincidental diseases, HSCT was proposed in 1993.245 Several cases of concomitant SLE and malignancy have been treated with HSCT and published. They include chronic myeloid leukemia/SLE,166 non-Hodgkin lymphoma (NHL)/SLE,157 and Hodgkin disease/SLE.160 The first patient eventually died of his leukemia without any evidence of active SLE. In another case, the NHL did not relapse, but ITP supervened in conjunction with an anticentromere antibody.163 The first patient with SLE received a transplantation of her own
T-cell-depleted marrow in 1996.199 The first report on
HSCT for SLE in the United States was published 1 year later in
1997.183 There are now several fully published case
reports of nonconcomitant SLE patients having undergone HSCT (Table
2).181-184,192,199,246 All
received transplantations of cyclophosphamide and G-CSF-mobilized CD34+ cells, and conditioning regimens varied from Cy/TT to
Cy/ATG (200 mg) to BEAM. All patients reached complete remission, but in several there was a serologic antinuclear antibody (ANA) relapse after 2 to 3 years from transplantation. In the patient with the longest posttransplantation follow-up, after 3 years of corticoid-free remission, there was a reappearance of ANA/DNA antibodies, and, after
another year, there was also a mild proteinuria, which is currently
being treated with a combination of corticosteroids and mycophenolate
mofetil.247
In the most extensive single-center clinical study published to date,181 9 patients underwent stem cell mobilization with cyclophosphamide 2.0 g/m2 and G-CSF 10 µg/kg. Two patients were excluded from transplantation because of infection (one death from disseminated mucormycosis), and 7 received autotransplantations after conditioning with cyclophosphamide (200 mg/kg), 3.0 g methylprednisolone, and 90 mg/kg equine antithymocyte globulin. All patients were seriously ill, with SLE disease activity indices of 17 to 37, including 1 case with alveolar hemorrhage and 4 with World Health Organization class III-IV glomerulonephritis and nephrotic syndrome. Lupus remained in clinical remission, and ANA became negative in all patients with 1 to 3 years of posttransplantation follow-up. Phase 3 trials are being designed in the United States to compare autologous HSCT with a control arm. The standard of care for the control arm has generated a great deal of discussion and controversy within the working group. Potential controls could be intravenous pulse cyclophosphamide, oral cyclophosphamide, mycophenolate mofetil, or an open control of best available care. American experience with oral cyclophosphamide or mycophenolate mofetil in SLE is limited. Pulse cyclophosphamide (500-1000mg/m2) has a long track record and is generally considered the standard of care. If HSCT candidates are selected for failure to pulse cyclophosphamide, it is difficult to continue failed therapy as on the control arm. One solution is to offer HSCT earlier in disease. Eligible patients with nonrenal visceral involvement need only fail corticosteroids and 3 months of pulse cyclophosphamide. For patients in whom the indication is nephritis, active disease must be present despite at least 6 cycles of monthly pulse cyclophosphamide. Enrolling patients earlier in disease who are less ill would also decrease the morbidity and mortality of HSCT. A second solution is to allow patients enrolled on the pulse cyclophosphamide arm who continue to fail to crossover to HSCT. Numerous SLE disease activity indices exist to measure disease activity including the British Isles Lupus Assessment Group scale (BILAG),248 Systemic Lupus Erythematosus Disease Activity Index,249 Systemic Lupus Activity Measure,250 and the Lupus Activity Index.251 The index used depends on institutional and investigator familiarity. In the American phase 3 trial of HSCT for SLE, the disease activity instrument will be the BILAG. BILAG is one of the more useful instruments for characterizing disease stage because BILAG score correlates with necessity to treat and has been validated as an instrument to measure disease activity.252,253 The evaluation is based on a 5-category classification, characterizing the degree of symptoms attributed to active lupus for 86 questions based on the patient's history, examination, and laboratory results. The 5 categories of response are the following: not present, improving, same, worse, and new. The 86 questions are grouped into the following 8 systems: general, mucocutaneous, neurologic, musculoskeletal, cardiovascular and respiratory, vasculitis, renal, and hematologic. For each of the 8 systems, a severity grade (A to E) is calculated according to the scores. The following list indicates interpretation of each of the grades for each system: A, disease is active enough to need treatment; B, disease has the potential to need treatment soon; C, disease currently does not meet grade A or B criteria; D, disease has satisfactorily resolved; and E, disease has never been involved. Because a crossover arm is tentatively planned in the American phase 3 trial, the primary endpoint will be need to treat as defined by a BILAG grade A. Autologous HSCT for RA RA affects 1% of the North American population.254 It is an immune-mediated disease that involves joint synovium with formation of an inflammatory pannus that erodes cartilage and bone.255 The characteristic joint lesion in RA includes an increase in the numbers of both fibroblastlike and macrophagelike synoviocytes in the synovial intimal lining, infiltrating lymphocytes, plasma cells, monocytes, and macrophages. T cells comprise about 30% to 50% of synovial tissue cells. Synovial T cells have been demonstrated to have a restricted repertoire256,257 and to react to a variety of microbial antigens258 and self-antigens such as type II collagen epitopes.259 Synovial macrophages produce IL-1 and tumor necrosis factor (TNF-).260 RA fibroblastlike synoviocytes can
proliferate in an anchorage-independent manner, escape contact
inhibition,261 aggressively invade into cartilage when
coimplanted into severe combined immune deficient mice,262
and have somatic mutations of the p53 tumor suppressor
gene.263 These complexities underscore the shortcomings of
previous approaches designed to eliminate only one set of immune cells.
The most common rheumatoid symptoms are joint pain, swelling or deformity, morning stiffness, elevated sedimentation rate, and a positive rheumatoid factor. Extra-articular symptoms may occur, including rheumatoid nodules, vasculitis, and pulmonary interstitial fibrosis.264,265 Patients with more than 20 to 30 involved joints have a 5-year mortality of 40% to 60%.266-275 Despite newer therapeutic agents like anti-TNF drugs, about 5% to 10% of patients with RA continue to have a desperate need for better and more definitive therapies.276 Because RA may be associated with significant morbidity, oncogene mutation, loss of synoviocyte growth inhibition, and, in some patients, high mortality, it is perhaps surprising that it was not until 1997 that the first HSCT for RA was reported from Australia173 and the first American HSCT for RA reported in 1998.180 In general, the procedure has been well tolerated without mortality
(Table 3). HSCT offers an almost
immediate relief of symptoms. Patients become pain free, sometimes for
the first time in years. Activities required for daily living, such as
buttoning a shirt or combing hair, rapidly return to normal. Morning
stiffness resolves, rheumatoid nodules disappear, sedimentation rate
normalizes, and rheumatoid factor may disappear. Although these studies
demonstrated that high-dose cyclophosphamide was well tolerated with
marked improvements (American College of Rheumatology [ACR] 50 or ACR 70), a complete remission was unusual and relapse within 1 to 2 years
is common.173,175,180,277,278 There are suggestions of a
dose-response effect. A dose escalation study of cyclophosphamide at
100 mg/kg revealed transient 1- to 2-month responses but at 200 mg/kg
response duration increased to 18 to 20 months.174 Too few
myeloablative transplantations, for example a busulfan and
cyclophosphamide regimen, have been performed to determine if durable
remissions are feasible.
For an intense and expensive treatment such as HSCT to be considered for RA, sustained complete remissions or 70% improvement as defined by the ACR (ACR 70) must be achieved.279 Several modifications are being considered, including the use of the current easily tolerated nonmyeloablative yet highly immunosuppressive regimen with posttransplantation immune modulation, eg, a TNF inhibitor, cyclosporine A, and/or methotrexate; or the use of a more intense myeloablative regimen such as busulfan and cyclophosphamide. A European approach being proposed for phase 3 trials uses the current cyclophosphamide mobilization (2.0 to 4.0 g/m2) and cyclophosphamide conditioning (200 mg/kg) with posttransplantation immune modulation. The nontransplant arm will be cyclophosphamide mobilization only followed by maintenance methotrexate (John Snowden, verbal communication, May 2001). This approach assumes that RA is not curable but is more easily controlled with conventional therapies after HSCT. Continued posttransplantation immune suppression may increase the risk of posttransplantation opportunistic infections. The Australians, rather than comparing HSCT with another therapy, are randomizing patients with RA to HSCT with or without T-cell depletion of the autograft. The American and Israeli approach is to pilot phase 1/2 autologous HSCT studies by using more intense myeloablative regimens (fludarabine plus oral busulfan or intravenous Busulfex and cyclophosphamide) in the hope of inducing more durable remissions, while simultaneously developing mini-allogeneic HSCT protocols for patients with HLA-matched siblings. Autologous HSCT for scleroderma Scleroderma is a rare disorder with a prevalence of anywhere from 2 to 100 per one million people.280 Two subsets of scleroderma are generally recognized, limited and extensive cutaneous scleroderma. Limited cutaneous scleroderma is characterized by cutaneous involvement of acral areas (hands, face, feet, forearms) but not the trunk. Limited scleroderma generally has a good prognosis. Diffuse cutaneous scleroderma is characterized by truncal and acral skin involvement and early visceral (lung, renal, cardiac, gastrointestinal) involvement. For all patients with diffuse scleroderma, 5-year mortality is 25% to 30%.281 High skin scores,282 pulmonary, renal, or cardiac involvement is associated with a higher mortality of 40% to 50% within 5 years.282-286Scleroderma is characterized by fibrosis (ie, excessive deposition of
collagen in skin and visceral organs). The etiology of scleroderma is
unclear, and an autoimmune pathogenesis remains controversial. Unlike
MS, RA, and SLE, the MHC association is weak.287,288
Randomized trials of D-penicillamine, interferon- Support for an immune-mediated etiology include a variety of autoantibodies, including antitopoisomerase (Scl-70) antibodies,299,300 and anticentromere antibodies.301 Chronic GVHD is an immune-mediated disorder that is clinically and histologically similar to scleroderma.302-304 Similar to scleroderma, chronic GVHD is associated with tissue fibrosis and is slow to respond to immune suppression. GVHD is caused by allogeneic lymphocytes, and patients with scleroderma have been reported to have an increased incidence of allogeneic hematopoietic cellular microchimerism.305 Transplacental transfer of fetal lymphocytes to the mother may lead to mixed chimerism in postpartum females.306 Transplacental transfer of maternal lymphocytes to the fetus may cause mixed chimerism in males and nonparous females. Similar to scleroderma, GVHD is also associated with endothelial damage and elevated von Willebrand antigen.307 The perceived failure of immune therapies in both chronic GVHD and scleroderma may be due to neglect in recognizing or effectively treating an early inflammatory phase. Late fibrotic processes may progress and regress more slowly. Regardless of etiology, because of its poor prognosis and lack of effective therapies, patients with scleroderma are being enrolled in HSCT protocols.176,195 Early results indicate improved skin scores and activities of daily living but unchanged renal, cardiac, and pulmonary function. In a study of mostly European patients by using a variety of conditioning regimens, skin score generally improved with stabilization of lung function. Overall mortality was 27% because of 10% disease progression and 17% transplantation-related mortality.308 These results suggest that more careful selection of patients earlier in disease is necessary in the design of phase 3 trials. Phase 3 randomized trials of HSCT versus monthly pulse cyclophosphamide are accruing in Europe and are being designed in the United States. The primary endpoint of these trials is overall survival.
Animal models Animal autoimmunelike diseases that occur spontaneously (without known precipitating infection or immunization) are not cured by a syngeneic HSCT. In fact, disease may be transferred to a normal strain of mice by HSCT from the autoimmune-prone donor.309 Syngeneic HSCT in spontaneous-onset lupuslike disease of MRL/lpr mice resulted in only transient disease amelioration.310 Curing a spontaneous-onset autoimmunelike disease requires allogeneic HSCT from a nonautoimmune-prone donor.311-321 Murine spontaneous-onset lupuslike disease is cured by allogeneic HSCT from a normal donor strain.311,314,315,317 Spontaneous-onset diabetes in NOD mice is prevented by allogeneic HSCT from a nondiabetic prone strain316,319,321 and cured by combined pancreas and allogeneic HSCT from the same donor.318 In fact, the "tolerizing" effect322,323 of HSCs is best demonstrated by donor-specific organ tolerance when combining solid organ and marrow transplant from the same donor.Donor-specific organ tolerance was initially performed by lethally irradiating animals to ablate their marrow followed by allogeneic donor bone marrow transplantation.324-326 Although donor-specific tolerance is associated with hematopoietic chimerism, the cellular mechanism by which donor-specific tolerance arises is not fully understood.327 Fas ligand is a surface protein that can signal other cells expressing Fas to undergo apoptosis. Fas ligand expression appears to be necessary for donor marrow to induce donor organ tolerance, because hematopoietic-induced donor-specific tolerance does not occur in Fas knockout mice.328 Therefore, the mechanism of allogeneic HSCT-induced tolerance to solid organ grafts may be in part explained by donor-induced apoptotic deletion of graft reactive cells. It has been postulated that allogeneic HSCT may induce tolerance to autoimmune epitopes by a similar deletion of autoreactive repertoires, a phenomena termed graft versus autoimmunity (GVA).329,330 A graft-versus-disease effect has already been established as the mechanism of remission for several hematologic malignancies, first discovered in 1981 and termed graft versus leukemia.331,332 A putative GVA effect is supported by experiments showing that allogeneic chimerism by using a sublethal conditioning regimen followed by allogeneic transplantation can prevent the onset of diabetes and even reverse preexisting insulitis in NOD mice, whereas the same radiation protocol without allogeneic HSC is insufficient.333 With nonmyeloablative-conditioning regimens, spontaneous animal models of autoimmunity have been cured in the setting of mixed chimerism.333-336 These experimental findings support low-conditioning preparative regimens for allogeneic transplantations in human autoimmune diseases. Although in theory a GVA effect may be beneficial, the most significant toxicity of allogeneic HSCT is an immunologic reaction of donor cells against normal host tissues, a complication known as GVHD. Mini-conditioning may be associated with less GVHD compared with the more hazardous high-dose transplantation regimens. A lower GVHD risk may be due to reduced regimen-related tissue damage, decreased inflammatory cytokine release, decreased exposure of hidden tissue epitopes, and veto of alloreactive donor lymphocytes by hematopoietic cells of host origin, particularly CD8+ cells.337,338 Mini-transplantations are less likely to provide the danger signal hypothesized by Matzinger54 that is necessary to break peripheral tolerance. Allogeneic HSCT in patients with autoimmune diseases Anecdotal case reports of patients undergoing allogeneic HSCT for malignancy or aplastic anemia and a coincidental autoimmune disease have in most cases resulted in long-term remission of the autoimmune disease.339-353 Most patients maintain remission indefinitely after discontinuation of immune-suppressive prophylaxis for GVHD. An occasional patient has relapsed despite being chimeric (ie, 100% donor hematopoiesis). Chimeric analysis of peripheral blood for residual host hematopoiesis may, however, be falsely negative. Separation and analysis of lineage-specific subsets, such as only T cells, may reveal mixed chimerism (both donor and host cells) in only the T-cell lineage. The clinically asymptomatic donor may also have subclinical disease, such as rheumatoid factor positive, that could adoptively transfer the same disease for which the recipient received a transplant. Alternatively, because the patients are MHC matched, the donor and recipient may have similar non-MHC autoimmune genes that in the presence of host "factors," such as a persistent latent infectious agent or recurrent environmental exposure, may initiate de novo disease.HLA-matched sibling allogeneic transplantations have already been successfully performed for some hematologic autoimmune diseases, including a case of hemolytic anemia,354 pure red cell aplasia,355 and Evans syndrome.356,357 Phase 1 allogeneic HSCT trials using mini-conditioning regimens with and without lymphocyte-depleted grafts are being suggested and designed for autoimmune diseases. Just as in autologous HSCT, protocols will need to be tailored for each disease.
HSCT of autoimmune disorders has raised new expectations, opportunities, and questions. What is the best mobilization regimen? What is the optimal conditioning regimen? Does T-cell depletion of the graft result in self-tolerance and decreased relapse, or rather result in an increased risk of infections? Can we predict candidates likely to relapse after autologous HSCT? Is relapsed disease responsive to previously refractory therapy and easier to control? Is HSCT cost effective? What is the mechanism(s) of posttransplantation remission? Which, if any, diseases may be cured by an autologous graft and which will require an allograft? Encouraging phase 1 trials have propelled this field to phase 3 trials in MS, SLE, RA, and scleroderma. Completion of these trials should determine if autologous HSCT is better than current standards of care. Nonmyeloablative or reduced-intensity allogeneic transplantation protocols are being written, and advances in ex vivo stem cell expansion will soon be applied to autoimmune diseases to eliminate regimen-related neutropenia. Historically, most autoimmune diseases are incurable, and it was impractical to define complete remission. HSCT, whether allogeneic or even autologous, may change this axiom. Initial results suggest that clinical tolerance, that is no evidence of disease off all immune-suppressive medications with normal third-party immune responsiveness, is being achieved in at least some patients. However, further improvement of the efficacy and safety of both autologous and allogeneic stem cell transplantation procedures need to be developed, and larger cohorts of patients need to be studied to assess the full benefits of stem cell transplantation as a most promising new armamentarium for the treatment of autoimmune diseases.
Submitted May 30, 2001; accepted September 30, 2001.
Reprints: Richard K. Burt, Division of Immune Therapy and Autoimmune Disease, Northwestern University Medical Center, 320 E Superior, Searle Bldg, Rm 3-489, Chicago, IL 60611; e-mail: rburt{at}nwu.edu.
1. Rose NR, Bona C. Defining criteria for autoimmune diseases. Immunol Today. 1993;14:426-430[CrossRef][Medline] [Order article via Infotrieve]. 2. Marmont AM. Defining criteria for autoimmune diseases. Immunol Today. 1994;15:388[Medline] [Order article via Infotrieve]. 3. Harrington WJ, Minnich V, Hollinsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thriombocytopenic purpura. J Lab Clin Med. 1951;38:1-10.
4.
Gardnerova M, Eymard B, Morel E, et al.
The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn.
Neurology.
1997;48:50-54 5. Keesey K, Lindstrom J, Cokely H, Hermann C. Antiacetylcholine receptor antibody in neonatal myasthenia gravis. N Engl J Med. 1977;296:55[Medline] [Order article via Infotrieve]. 6. Yamada H, Kato EH, Kobashi G, et al. Passive immune thrombocytopenia in neonates of mothers with idiopathic thrombocytopenic purpura: incidence and risk factors. Semin Thromb Hemost. 1999;25:491-496[Medline] [Order article via Infotrieve].
7.
Burrows RF, Kelton JG.
Fetal thrombocytopenia and its relation to maternal thrombocytopenia.
N Engl J Med.
1993;329:1463-1466 8. Snowden JA, Heaton DC. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol. 1997;137:130-132[CrossRef][Medline] [Order article via Infotrieve]. 9. Neumeister P, Strunk D, Apfelbeck U, Sill H, Linkesch W. Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma Lancet. 2000;355:1334-1335[CrossRef][Medline] [Order article via Infotrieve]. 10. Berisso GA, van Lint MT, Bacigalupo A, Marmont AM. Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves' disease. Bone Marrow Transplant. 1999;23:1091-1092[CrossRef][Medline] [Order article via Infotrieve]. 11. Kishimoto Y, Yamamoto Y, Ito T, et al. Transfer of autoimmune thyroiditis and resolution of palmoplantar pustular psoriasis following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:1041-1043[CrossRef][Medline] [Order article via Infotrieve].
12.
Thomson JA, Wilson RM, Franklin IM.
Transmission of thyrotoxicosis of autoimmune type by sibling allogeneic bone marrow transplant.
Eur J Endocrinol.
1995;133:564-566 13. Aldouri MA, Ruggier R, Epstein O, Prentice HG. Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation for chronic myeloid leukaemia. Br J Haematol. 1990;74:118-119[Medline] [Order article via Infotrieve]. 14. Cohen IR. Discrimination and dialogue in the immune system. Semin Immunol. 2000;12:269-271[CrossRef][Medline] [Order article via Infotrieve]. 15. Burnet FM. A modification of Jerne's theory of antibody production using the concept of clonal selection. Aust J Sci. 1957;20:67. 16. Schwartz RH. A clonal deletion model for Ir gene control of the immune response. Scand J Immunol. 1978;7:3-10[CrossRef][Medline] [Order article via Infotrieve].
17.
Blackman M, Kappler J, Marrack P.
The role of the T cell receptor in positive and negative selection of developing T cells.
Science.
1990;248:1335-1341
18.
Smith H, Chen IM, Kubo R, Tung KS.
Neonatal thymectomy results in a repertoire enriched in T cells deleted in adult thymus.
Science.
1989;245:749-752 19. Lafferty KJ, Gazda LS. Tolerance: a case of self/not-self discrimination maintained by clonal deletion? Hum Immunol. 1997;52:119-126[CrossRef][Medline] [Order article via Infotrieve].
20.
Fry AM, Jones LA, Kruisbeek AM, Matis LA.
Thymic requirement for clonal deletion during T cell development.
Science.
1989;246:1044-1046 21. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell. 1987;49:273-280[CrossRef][Medline] [Order article via Infotrieve].
22.
Ramsdell F, Fowlkes BJ.
Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance.
Science.
1990;248:1342-1348
23.
Schwarz RH.
A cell culture model for T lymphocyte clonal anergy.
Science.
1990;248:1349-1356 24. Malvey EN, Telander DG, Vanasek TL, Mueller DL. The role of clonal anergy in the avoidance of autoimmunity: inactivation of autocrine growth without loss of effector function. Immunol Rev. 1998;165:301-318[CrossRef][Medline] [Order article via Infotrieve].
25.
Ramsdell F, Lantz T, Fowlkes BJ.
A nondeletional mechanism of thymic self tolerance.
Science.
1989;246:1038-1041
26.
Bevan MJ, Hogquist KA, Jameson SC.
Selecting the T cell receptor repertoire.
Science.
1994;264:796-797 27. Ashton-Rickardt PG, Tonegawa S. A differential-avidity model for T-cell selection. Immunol Today. 1994;15:362-366[CrossRef][Medline] [Order article via Infotrieve].
28.
Sebzda E, Wallace VA, Mayer J, Yeung RS, Mak TW, Ohashi PS.
Positive and negative thymocyte selection induced by different concentrations of a single peptide.
Science.
1994;263:1615-1618 29. Miller JF, Morahan G. Peripheral T cell tolerance. Annu Rev Immunol. 1992;10:51-69[CrossRef][Medline] [Order article via Infotrieve]. 30. Bretscher P. Contemporary models for peripheral tolerance and the classical "historical postulate." Semin Immunol. 2000;12:221-229[CrossRef][Medline] [Order article via Infotrieve]discussion 257-344.
31.
Bretscher P, Cohn M.
A theory of self-nonself discrimination.
Science.
1970;169:1042-1049
32.
Freeman GJ, Gribben JG, Boussiotis VA, et al.
Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
Science.
1993;262:909-911 33. Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76-79[CrossRef][Medline] [Order article via Infotrieve]. 34. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today. 1994;15:321-331[CrossRef][Medline] [Order article via Infotrieve].
35.
Fraser JD, Irving BA, Crabtree GR, Weiss A.
Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28.
Science.
1991;251:313-316 36. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356:607-609[CrossRef][Medline] [Order article via Infotrieve].
37.
Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB.
Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway.
Science.
1989;244:339-343 38. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;97:263-266. 39. Cocks BG, Chang CC, Carballido JM, Yssel H, de Vries JE, Aversa G. A novel receptor involved in T-cell activation. Nature. 1995;376:260-263[CrossRef][Medline] [Order article via Infotrieve].
40.
Shahinian A, Pfeffer K, Lee KP, et al.
Differential T cell costimulatory requirements in CD28-deficient mice.
Science.
1993;261:609-612 41. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 1996;153:85-106[CrossRef][Medline] [Order article via Infotrieve]. 42. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922[CrossRef][Medline] [Order article via Infotrieve].
43.
Grewal IS, Foellmer HG, Grewal KD, et al.
Requirement for CD40 ligand costimulation induction, T cell activation, and experimental allergic encephalomyelitis.
Science.
1996;273:1864-1867 44. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev. 1997;156:199-209[CrossRef][Medline] [Order article via Infotrieve]. 45. Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic "ignorance" of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med. 2000;6:686-688[CrossRef][Medline] [Order article via Infotrieve].
46.
Jones LA, Chin LT, Longo DL, Kruisbeek AM.
Peripheral clonal elimination of functional T cells.
Science.
1990;250:1726-1729
47.
Bertolino P, Trescol-Biemont MC, Thomas J, et al.
Death by neglect as a deletional mechanism of peripheral tolerance.
Int Immunol.
1999;11:1225-1238 48. Pender MP. Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance. Immunol Cell Biol. 1999;77:216-223[CrossRef][Medline] [Order article via Infotrieve]. 49. Shevach EM. Suppressor T cells: rebirth, function and homeostasis. Curr Biol. 2000;10:R572-R575[CrossRef][Medline] [Order article via Infotrieve]. 50. Shevach EM. Regulatory T cells in autoimmmunity*. Annu Rev Immunol. 2000;18:423-449[CrossRef][Medline] [Order article via Infotrieve]. 51. Roncarolo MG, Levings MK. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol. 2000;12:676-683[CrossRef][Medline] [Order article via Infotrieve].
52.
Garza KM, Agersborg SS, Baker E, Tung KS.
Persistence of physiological self antigen is required for the regulation of self tolerance.
J Immunol.
2000;164:3982-3989
53.
Critchfield JM, Racke MK, Zuniga-Pflucker JC, et al.
T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis.
Science.
1994;263:1139-1143 54. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045[Medline] [Order article via Infotrieve].
55.
Laird DJ, De Tomaso AW, Cooper MD, Weissman IL.
50 million years of chordate evolution: seeking the origins of adaptive immunity.
Proc Natl Acad Sci U S A.
2000;97:6924-6926
56.
Medzhitov R, Janeway C Jr.
Innate immunity.
N Engl J Med.
2000;343:338-344 57. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science. 1996;272:50-53[Abstract]. 58. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol. 1997;9:4-9[CrossRef][Medline] [Order article via Infotrieve]. 59. Lo D, Feng L, Li L, et al. Integrating innate and adaptive immunity in the whole animal. Immunol Rev. 1999;169:225-239[CrossRef][Medline] [Order article via Infotrieve].
60.
Grossman Z, Singer A.
Tuning of activation thresholds explains flexibility in the selection and development of T cells in the thymus.
Proc Natl Acad Sci U S A.
1996;93:14747-14752 61. Grossman Z, Paul WE. Self-tolerance: context dependent tuning of T cell antigen recognition. Semin Immunol. 2000;12:197-203[CrossRef][Medline] [Order article via Infotrieve]discussion 257-344.
62.
Grossman Z, Paul WE.
Adaptive cellular interactions in the immune system: the tunable activation threshold and the significance of subthreshold responses.
Proc Natl Acad Sci U S A.
1992;89:10365-10369 63. Uetrecht JP. Current trends in drug-induced autoimmunity. Toxicology. 1997;119:37-43[CrossRef][Medline] [Order article via Infotrieve]. 64. Rose NR. The role of infection in the pathogenesis of autoimmune disease. Semin Immunol. 1998;10:5-13[CrossRef][Medline] [Order article via Infotrieve]. 65. Steinman L, Conlon P. Viral damage and the breakdown of self-tolerance. Nat Med. 1997;3:1085-1087[CrossRef][Medline] [Order article via Infotrieve]. 66. Kretz-Rommel A, Rubin RL. Disruption of positive selection of thymocytes causes autoimmunity. Nat Med. 2000;6:298-305[CrossRef][Medline] [Order article via Infotrieve]. 67. Rubin RL, Kretz-Rommel A. Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus. Environ Health Perspect. 1999;107(suppl 5):803-806. 68. Rubin RL. Etiology and mechanisms of drug-induced lupus. Curr Opin Rheumatol. 1999;11:357-363[CrossRef][Medline] [Order article via Infotrieve].
69.
Jenkins MK, Schwartz RH, Pardoll DM.
Effects of cyclosporine A on T cell development and clonal deletion.
Science.
1988;241:1655-1658
70.
Chen W, Thoburn C, Hess AD.
Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft-versus-host disease.
J Immunol.
1998;161:7040-7046 71. Homma M, van Breda Vriesman PJ, Damoiseaux JG. Defective de novo thymocyte maturation in cyclosporin A (CsA)-induced autoimmunity: expression of costimulatory and activation molecules. Clin Exp Immunol. 1997;110:79-85[CrossRef][Medline] [Order article via Infotrieve]. 72. Damoiseaux JG, Beijleveld LJ, van Breda Vriesman PJ. Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. Clin Immunol Immunopathol. 1997;82:197-202[CrossRef][Medline] [Order article via Infotrieve]. 73. Douek DC, Vescio RA, Betts MR, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet. 2000;355:1875-1881[CrossRef][Medline] [Order article via Infotrieve]. 74. Douek DC, Koup RA. Evidence for thymic function in the elderly. Vaccine. 2000;18:1638-1641[CrossRef][Medline] [Order article via Infotrieve]. 75. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690-695[CrossRef][Medline] [Order article via Infotrieve]. 76. Benoist C, Mathis D. Autoimmune diabetes. Retrovirus as trigger, precipitator or marker? Nature. 1997;388:833-834[Medline] [Order article via Infotrieve]. 77. Vague P, Vialettes B, Prince MA, de Micco P. Coxsackie B viruses and autoimmune diabetes. N Engl J Med. 1981;305:1157-1158[Medline] [Order article via Infotrieve]. 78. Karam JH, Grodsky GM, Forsham PH. Coxsackie viruses and diabetes. Lancet. 1971;2:1209[Medline] [Order article via Infotrieve]. 79. Anonymous. Coxsackie viruses and diabetes. Lancet. 1971;2:804[Medline] [Order article via Infotrieve].
80.
Ringrose JH.
HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?
Ann Rheum Dis.
1999;58:598-610 81. Hafler DA. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J Clin Invest. 1999;104:527-529[Medline] [Order article via Infotrieve]. 82. Salmi AA, Panelius M, Halonen P, Rinne UK, Penttinen K. Measles virus antibody in cerebrospinal fluids from patients with multiple sclerosis. Br Med J. 1972;1:477-479. 83. Berti R, Soldan SS, Akhyani N, McFarland HF, Jacobson S. Extended observations on the association of HHV-6 and multiple sclerosis. J Neurovirol. 2000;6(suppl 2):S85-S87. 84. Haahr S, Munch M. The association between multiple sclerosis and infection with Epstein-Barr virus and retrovirus. J Neurovirol. 2000;6(suppl 2):S76-S79. 85. Monteyne P, Bureau JF, Brahic M. Viruses and multiple sclerosis. Curr Opin Neurol. 1998;11:287-291[CrossRef][Medline] [Order article via Infotrieve].
86.
Ferrante P, Omodeo-Zorini E, Caldarelli-Stefano R, et al.
Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients.
Mult Scler.
1998;4:49-54 87. Rose NR, Neumann DA, Herskowitz A. Coxsackie virus myocarditis. Adv Intern Med. 1992;37:411-429[Medline] [Order article via Infotrieve]. 88. Penninger JM, Bachmaier K. Review of microbial infections and the immune response to cardiac antigens. J Inf Dis. 2000;181(suppl 3):S498-S504. 89. Anonymous. Dilated cardiomyopathy and enteroviruses. Lancet. 1990;336:971-973[CrossRef][Medline] [Order article via Infotrieve]. 90. Rook G, Lydyard P, Stanford J. Mycobacteria and rheumatoid arthritis. Arthritis Rheum. 1990;33:431-435[Medline] [Order article via Infotrieve].
91.
Hakkarainen K, Turunen H, Miettinen A, Karppelin M, Kaitila K, Jansson E.
Mycoplasmas and arthritis.
Ann Rheum Dis.
1992;51:1170-1172
92.
Small P.
Rheumatoid arthritis
93.
Taylor-Robinson D, Thomas BJ, Dixey J, Osborn MF, Furr PM, Keat AC.
Evidence that Chlamydia trachomatis causes seronegative arthritis in women.
Ann Rheum Dis.
1988;47:295-299 94. Takeda T, Mizugaki Y, Matsubara L, Imai S, Koike T, Takada K. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:1218-1225[CrossRef][Medline] [Order article via Infotrieve]. 95. Blaschke S, Schwarz G, Moneke D, Binder L, Muller G, Reuss-Borst M. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J Rheumatol. 2000;27:866-873[Medline] [Order article via Infotrieve]. 96. Zhang D, Nikkari S, Vainionpaa R, Luukkainen R, Yli-Kerttula U, Toivanen P. Detection of rubella, mumps, and measles virus genomic RNA in cells from synovial fluid and peripheral blood in early rheumatoid arthritis. J Rheumatol. 1997;24:1260-1265[Medline] [Order article via Infotrieve]. 97. Kowal C, Weinstein A, Diamond B. Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus. Eur J Immunol. 1999;29:1901-1911[CrossRef][Medline] [Order article via Infotrieve].
98.
Albert LJ, Inman RD.
Molecular mimicry and autoimmunity.
N Engl J Med.
1999;341:2068-2074 99. Benoist C, Mathis D. Autoimmunity. The pathogen connection. Nature. 1998;394:227-228[CrossRef][Medline] [Order article via Infotrieve]. 100. Vanderlugt CL, Begolka WS, Neville KL, et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev. 1998;164:63-72[CrossRef][Medline] [Order article via Infotrieve]. 101. Mamula MJ. Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol Rev. 1998;164:231-239[CrossRef][Medline] [Order article via Infotrieve].
102.
Ehl S, Hombach J, Aichele P, Hengartner H, Zinkernagel RM.
Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model.
J Exp Med.
1997;185:1241-1251 103. Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-"vaccinosis": a dangerous liaison? J Autoimmun. 2000;14:1-10[CrossRef][Medline] [Order article via Infotrieve]. 104. Miller SD, Gerety SJ. Immunologic aspects of Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. Semin Virol. 1990;1:263-272. 105. Miller SD, Vanderlugt CL, Begolka WS, et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med. 1997;3:1133-1136[CrossRef][Medline] [Order article via Infotrieve]. 106. Posnett DN. Do superantigens play a role in autoimmunity? Semin Immunol. 1993;5:65-72[CrossRef][Medline] [Order article via Infotrieve]. 107. Torres BA, Johnson HM. Modulation of disease by superantigens. Curr Opin Immunol. 1998;10:465-470[CrossRef][Medline] [Order article via Infotrieve]. 108. Fraser J, Arcus V, Kong P, Baker E, Proft T. Superantigens-powerful modifiers of the immune system. Mol Med Today. 2000;6:125-132[CrossRef][Medline] [Order article via Infotrieve]. 109. Macphail S. Superantigens: mechanisms by which they may induce, exacerbate and control autoimmune diseases. Int Rev Immunol. 1999;18:141-180[Medline] [Order article via Infotrieve]. 110. Li H, Llera A, Malchiodi EL, Mariuzza RA. The structural basis of T cell activation by superantigens. Annu Rev Immunol. 1999;17:435-466[CrossRef][Medline] [Order article via Infotrieve]. 111. Brocke S, Hausmann S, Steinman L, Wucherpfennig KW. Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system. Semin Immunol. 1998;10:57-67[CrossRef][Medline] [Order article via Infotrieve]. 112. Schiffenbauer J, Soos J, Johnson H. The possible role of bacterial superantigens in the pathogenesis of autoimmune disorders. Immunol Today. 1998;19:117-120[CrossRef][Medline] [Order article via Infotrieve]. 113. Vanderlugt CL, Miller SD. Epitope spreading. Curr Opin Immunol. 1996;8:831-836[CrossRef][Medline] [Order article via Infotrieve].
114.
Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, Miller SD.
Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.
J Immunol.
2000;164:670-678 115. Heath VL, Hutchings P, Fowell DJ, Cooke A, Mason DW. Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. Diabetes. 1999;48:2157-2165[Abstract]. 116. Agius MA, Twaddle GM, Fairclough RH. Epitope spreading in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci. 1998;841:365-367[CrossRef][Medline] [Order article via Infotrieve].
117.
Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R.
Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence.
Brain.
2000;123:508-518 118. Orth T, Mayet WJ, Deister H, Chang S, Schmitz M, Bachmann M. Analysis of epitope spreading over an eleven-year period in a patient with systemic lupus erythematosus. Scand J Rheumatol. 1998;27:461-464[CrossRef][Medline] [Order article via Infotrieve].
119.
Chan LS.
Epitope spreading in paraneoplastic pemphigus: autoimmune induction in antibody-mediated blistering skin diseases.
Arch Dermatol.
2000;136:663-664 120. Wang ZY, Okita DK, Howard JF Jr, Conti-Fine BM. CD4+ epitope spreading and differential T cell recognition of muscle acetylcholine receptor subunits in myasthenia gravis. Ann N Y Acad Sci. 1998;841:334-337[CrossRef][Medline] [Order article via Infotrieve]. 121. Bonifacio E, Lampasona V, Bernasconi L, Ziegler AG. Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. Diabetes. 2000;49:202-208[Abstract].
122.
Naserke HE, Ziegler AG, Lampasona V, Bonifacio E.
Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes.
J Immunol.
1998;161:6963-6969 123. Yang L, DuTemple B, Gorczynski RM, Levy G, Zhang L. Evidence for epitope spreading and active suppression in skin graft tolerance after donor-specific transfusion. Transplantation. 1999;67:1404-1410[CrossRef][Medline] [Order article via Infotrieve]. 124. Suciu-Foca N, Ciubotariu R, Colovai A, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection. Transplant Proc. 1999;31:100-101[CrossRef][Medline] [Order article via Infotrieve]. 125. Ciubotariu R, Liu Z, Colovai AI, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest. 1998;101:398-405[Medline] [Order article via Infotrieve]. 126. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 1974;248:701-702[CrossRef][Medline] [Order article via Infotrieve]. 127. Zinkernagel RM. The Nobel Lectures in Immunology. The Nobel Prize for Physiology or Medicine, 1996. Cellular immune recognition and the biological role of major transplantation antigens. Scand J Immunol. 1997;46:421-436[CrossRef][Medline] [Order article via Infotrieve]. 128. Nepom GT, Erlich H. MHC class-II molecules and autoimmunity. Annu Rev Immunol. 1991;9:493-525[CrossRef][Medline] [Order article via Infotrieve]. 129. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30:1205-1213[Medline] [Order article via Infotrieve].
130.
Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, Bell JI.
HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region.
Proc Natl Acad Sci U S A.
1989;86:10049-10053 131. Nepom GT. HLA and rheumatoid arthritis. In: Lechler R,Warrens A, eds. HLA in Health and Disease. 2nd ed. London, United Kingdom: Academic Press; 2000:181-185.
132.
Breur-Vriesendorp BS, Dekker-Saeys AJ, Ivanyi P.
Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: the disease is associated with a common determinant of the various B27 molecules.
Ann Rheum Dis.
1987;46:353-356 133. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol. 1995;12:107-128[Medline] [Order article via Infotrieve]. 134. Theofilopoulos AN, ed. Genes and Genetics of Autoimmunity. Basel, Switzerland: Karger; 1999:1-285. 135. Ghosh S, Palmer SM, Rodrigues NR, et al. Polygenic control of autoimmune diabetes in non-obese diabetic mice. Nat Genet. 1993;4:404-409[CrossRef][Medline] [Order article via Infotrieve]. 136. Rudofsky UH, Lawrence DA. New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects. Environm Health Perspect. 1999;107(suppl 5):713-721. 137. Wakeland EK, Wandstrat AE, Liu K, Morel L. Genetic dissection of systemic lupus erythematosus. Curr Opin Immunol. 1999;11:701-707[CrossRef][Medline] [Order article via Infotrieve]. 138. Wooley PH. Animal models of rheumatoid arthritis. Curr Opin Rheumatol. 1991;3:407-420[Medline] [Order article via Infotrieve]. 139. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 1997;61:1861-1878[CrossRef][Medline] [Order article via Infotrieve]. 140. Remmers EF, Longman RE, Du Y, et al. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. Nat Genet. 1996;14:82-85[CrossRef][Medline] [Order article via Infotrieve]. 141. Griffiths MM, Wang J, Joe B, et al. Identification of four new quantitative trait loci regulating arthritis severity and one new quantitative trait locus regulating autoantibody production in rats with collagen-induced arthritis. Arthritis Rheum. 2000;43:1278-1289[CrossRef][Medline] [Order article via Infotrieve].
142.
Hawkes CH.
Twin studies in medicine 143. van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol. 2000;20:10-16[CrossRef][Medline] [Order article via Infotrieve]. 144. Karussis D, Vourka-Karussis U, Mizrachi-Koll R, Abramsky O. Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult Scler. 1999;5:17-21[CrossRef][Medline] [Order article via Infotrieve]. 145. Kamiya M, Sohen S, Yamane T, Tanaka S. Effective treatment of mice with type II collagen induced arthritis with lethal irradiation and bone marrow transplantation. J Rheumatol. 1993;20:225-230[Medline] [Order article via Infotrieve].
146.
Burt RK, Padilla J, Begolka WS, Canto MCD, Miller SD.
Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis.
Blood.
1998;91:2609-2616 147. van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant. 1996;18:1029-1034[Medline] [Order article via Infotrieve]. 148. Blank M, Tomer Y, Slavin S, Shoenfeld Y. Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation. Scand J Immunol. 1995;42:226-234[CrossRef][Medline] [Order article via Infotrieve]. 149. Karussis DM, Vourka-Karussis U, Lehmann D, et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest. 1993;92:765-772. 150. van Gelder M, Kinwel-Bohre EP, van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant. 1993;11:233-241[Medline] [Order article via Infotrieve]. 151. Burt RK, Burns W, Ruvolo P, et al. Syngeneic bone marrow transplantation eliminates V beta 8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res. 1995;41:526-531[CrossRef][Medline] [Order article via Infotrieve]. 152. Knaan-Shanzer S, Houben P, Kinwel-Bohre EP, van Bekkum DW. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. Bone Marrow Transplant. 1991;8:333-338[Medline] [Order article via Infotrieve]. 153. Pestronk A, Drachman DB, Teoh R, Adams RN. Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Ann Neurol. 1983;14:235-241[CrossRef][Medline] [Order article via Infotrieve]. 154. van Bekkum DW. Conditioning regimens for the treatment of experimental arthritis with autologous bone marrow transplantation. Bone Marrow Transplant. 2000;25:357-364[CrossRef][Medline] [Order article via Infotrieve].
155.
van Bekkum DW, Bohre EP, Houben PF, Knaan-Shanzer S.
Regression of adjuvant-induced arthritis in rats following bone marrow transplantation.
Proc Natl Acad Sci U S A.
1989;86:10090-10094
156.
Burt RK, Padilla J, Dal Canto MC, Miller SD.
Viral hyperinfection of the central nervous system and high mortality after hematopoietic stem cell transplantation for treatment of Theiler's murine encephalomyelitis virus-induced demyelinating disease.
Blood.
1999;94:2915-2922 157. Snowden JA, Patton WN, O'Donnell JL, Hannah EE, Hart DN. Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997;19:1247-1250[CrossRef][Medline] [Order article via Infotrieve]. 158. Demirer T, Celebi H, Arat M, et al. Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24:335-337[CrossRef][Medline] [Order article via Infotrieve]. 159. Jindra P, Koza V, Fiser J, Vozobulova V, Svojgrova M. Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: complete remission of lymphoma with control of autoimmune complications. Bone Marrow Transplant. 1999;24:215-217[CrossRef][Medline] [Order article via Infotrieve]. 160. Schachna L, Ryan PF, Schwarer AP. Malignancy-associated remission of systemic lupus erythematosus maintained by autologous peripheral blood stem cell transplantation. Arthritis Rheum. 1998;41:2271-2272[CrossRef][Medline] [Order article via Infotrieve]. 161. Rosler W, Manger B, Repp R, Kalden JR, Gramatzki M. Autologous PBPCT in a patient with lymphoma and Sjogren's syndrome: complete remission of lymphoma without control of the autoimmune disease. Bone Marrow Transplant. 1998;22:211-213[CrossRef][Medline] [Order article via Infotrieve]. 162. Cooley HM, Snowden JA, Grigg AP, Wicks IP. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis Rheum. 1997;40:1712-1715[Medline] [Order article via Infotrieve].
163.
Euler HH, Marmont AM, Bacigalupo A, et al.
Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation
Blood.
1996;88:3621-3625 164. Musso M, Porretto F, Crescimanno A, Bondi F, Polizzi V, Scalone R. Crohn's disease complicated by relapsed extranodal Hodgkin's lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant. Bone Marrow Transplant. 2000;26:921-923[CrossRef][Medline] [Order article via Infotrieve].
165.
Meloni G, Capria S, Vignetti M, Mandelli F, Modena V.
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Blood.
1997;89:4659
166.
Meloni G, Capria S, Salvetti M, Cordone I, Mancini M, Mandelli F.
Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia.
Haematologica.
1999;84:665-667 167. Burt RK, Fassas A, Snowden J, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant. 2001;28:1-12[CrossRef][Medline] [Order article via Infotrieve].
168.
Openshaw H, Stuve O, Antel JP, et al.
Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor.
Neurology.
2000;54:2147-2150 169. Nash RA, Kraft GH, Bowen JD, et al. Treatment of severe multiple sclerosis (MS) with high dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT) [abstract]. Blood. 2000;96(suppl):842a. 170. Martino R, Sureda A, Brunet S. Peripheral blood stem cell mobilization in refractory autoimmune Evans syndrome: a cautionary case report. Bone Marrow Transplant. 1997;20:521[CrossRef][Medline] [Order article via Infotrieve]. 171. Slavin S. Treatment of life-threatening autoimmune diseases with myeloablative doses of immunosuppressive agents: experimental background and rationale for ABMT. Bone Marrow Transplant. 1993;12:85-88[Medline] [Order article via Infotrieve].
172.
Brodsky RA, Petri M, Smith BD, et al.
Immunablative high dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease.
Ann Intern Med.
1998;129:1031-1035 173. Joske DJ, Ma DT, Langlands DR, Owen ET. Autologous bone-marrow transplantation for rheumatoid arthritis [letter]. Lancet. 1997;350:337[CrossRef][Medline] [Order article via Infotrieve]. 174. Snowden JA, Biggs JC, Milliken ST, Fuller A, Brooks PM. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum. 1999;42:2286-2292[CrossRef][Medline] [Order article via Infotrieve].
175.
McColl G, Kohsaka H, Szer J, Wicks I.
High-dose chemotherapy and syngeneic hemopoietic stem-cell transplantation for severe, seronegative rheumatoid arthritis.
Ann Int Med.
1999;131:507-509 176. Tyndall A, Black C, Finke J, et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell Lancet. 1997;349:254[Medline] [Order article via Infotrieve]. 177. Lim SH, Kell J, al-Sabah A, Bashi W, Bailey-Wood R. Peripheral blood stem-cell transplantation for refractory autoimmune thrombocytopenic purpura [letter]. Lancet. 1997;349:475[CrossRef][Medline] [Order article via Infotrieve]. 178. Pavletic S, O'Dell J, Ursick M, et al. Autologous blood stem cell transplantation can overcome and modulate therapeutic resistance in severe rheumatoid arthritis [abstract]. Blood. 1999;94:404b.
179.
Burt RK, Traynor AE, Pope R, et al.
Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation.
Blood.
1998;92:3505-3514 180. Burt RK, Georganas C, Schroeder J, et al. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: sustained response in two of four patients. Arthritis Rheum. 1999;42:2281-2285[CrossRef][Medline] [Order article via Infotrieve]. 181. Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet. 2000;356:701-707[CrossRef][Medline] [Order article via Infotrieve].
182.
Traynor A, Burt RK.
Haematopoietic stem cell transplantation for active systemic lupus erythematosus.
Rheumatology (Oxford).
1999;38:767-772
183.
Burt RK, Traynor A, Ramsey-Goldman R.
Hematopoietic stem-cell transplantation for systemic lupus erythematosus.
N Engl J Med.
1997;337:1777-1778
184.
Musso M, Porretto F, Crescimanno A, et al.
Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome.
Lupus.
1998;7:492-494 185. Musso M, Porretto F, Crescimanno A, et al. Successful treatment of resistant thrombotic thrombocytopenic purpura/hemolytic uremic syndrome with autologous peripheral blood stem and progenitor (CD34+) cell transplantation. Bone Marrow Transplant. 1999;24:207-209[CrossRef][Medline] [Order article via Infotrieve]. 186. Quartier P, Prieur AM, Fischer A. Haemopoietic stem-cell transplantation for juvenile chronic arthritis [letter]. Lancet. 1999;353:1885-1886[Medline] [Order article via Infotrieve]. 187. Martini A, Maccario R, Ravelli A, et al. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis Rheum. 1999;42:807-811[CrossRef][Medline] [Order article via Infotrieve]. 188. Rosen O, Thiel A, Massenkeil G, et al. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res. 2000;2:327-336[CrossRef][Medline] [Order article via Infotrieve]. 189. Kozak T, Havrdova E, Pit'ha J, et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant. 2000;25:525-531[CrossRef][Medline] [Order article via Infotrieve].
190.
Fassas A, Anagnostopoulos A, Kazis A, et al.
Autologous stem cell transplantation in progressive multiple sclerosis 191. Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997;20:631-638[CrossRef][Medline] [Order article via Infotrieve].
192.
Fouillard L, Gorin NC, Laporte JP, Leon A, Brantus JF, Miossec P.
Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood.
Lupus.
1999;8:320-323 193. Burt RK, Traynor AE, Cohen B, et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant. 1998;21:537-541[CrossRef][Medline] [Order article via Infotrieve]. 194. Wulffraat N, van Royen A, Bierings M, Vossen J, Kuis W. Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet. 1999;353:550-553[CrossRef][Medline] [Order article via Infotrieve]. 195. McSweeney PA, Furst DE, Storek J, et al. High dose immune suppressive therapy (HDIT) using total body irradiation (TBI) cyclophosphamide (CY) and ATG with autologous CD34+ selected peripheral blood stem cell (PBSC) rescue as treatment for severe systemic sclerosis [abstract]. Blood. 1998;92(suppl):285. 196. Durez P, Toungouz M, Schandene L, Lambermont M, Goldman M. Remission and immune reconstitution after T-cell-depleted stem-cell transplantation for rheumatoid arthritis. Lancet. 1998;352:881[Medline] [Order article via Infotrieve]. 197. Openshaw H, Lund BT, Kashyap A, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant. 2000;6:563-575[CrossRef][Medline] [Order article via Infotrieve]. 198. Baron F, Ribbens C, Kaye O, Fillet G, Malaise M, Beguin Y. Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation. Br J Haematol. 2000;110:339-342[CrossRef][Medline] [Order article via Infotrieve].
199.
Marmont AM, van Lint MT, Gualandi F, Bacigalupo A.
Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration.
Lupus.
1997;6:545-548 200. Marmont AM, van Lint MT, Occhini D, Lamparelli T, Bacigalupo A. Failure of autologous stem cell transplantation in refractory thrombocytopenic purpura. Bone Marrow Transplant. 1998;22:827-828[CrossRef][Medline] [Order article via Infotrieve]. 201. Squires DJ, Lamerton LF. The effect of various cytotoxic agents on bone marrow progenitor cells as measured by diffusion chamber assays. Br J Haematol. 1975;29:31-42[Medline] [Order article via Infotrieve]. 202. Urowitz MB, Rider WD. Myeloproliferative disorders in patients with rheumatoid arthritis treated with total body irradiation. Am J Med. 1985;78:60-64[CrossRef][Medline] [Order article via Infotrieve]. 203. Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129:630-632[CrossRef][Medline] [Order article via Infotrieve].
204.
Curtis RE, Rowlings PA, Deeg HJ, et al.
Solid cancers after bone marrow transplantation.
N Engl J Med.
1997;336:897-904
205.
Tyndall A, Fassas A, Passweg J, et al.
Autologous haematopoietic stem cell transplants for autoimmune disease 206. Gjertson DW. Update: center effects. Clinical Transplants.; 1990:375-383.
207.
Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S.
Vaccinations and the risk of relapse in multiple sclerosis.
N Engl J Med.
2001;344:319-326
208.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG.
Multiple sclerosis.
N Engl J Med.
2000;343:938-952 209. Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol. 1998;18:301-307[Medline] [Order article via Infotrieve]. 210. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin. 1995;13:119-146[Medline] [Order article via Infotrieve]. 211. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol. 1994;36(suppl):S6-S11.
212.
Paty DW, Li DK, UBC MS/MRI Study Group, and IFNB Multiple Sclerosis Study Group.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial.
Neurology.
1993;43:662-667
213.
The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group.
Interferon (beta)-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial.
Neurology.
1995;45:1277-1285 214. PRISMS (Prevention of Relapses and Disability by Interferon (beta)-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis [erratum in Lancet. 1999;353:678]. Lancet. 1998;352:1498-1504[CrossRef][Medline] [Order article via Infotrieve]. 215. European Study Group on Interferon (beta)-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon (beta)-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491-1497[CrossRef][Medline] [Order article via Infotrieve].
216.
The IFNB Multiple Sclerosis Study Group.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.
Neurology.
1993;43:655-661
217.
Johnson KP, Brooks BR, Cohen JA, et al.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial.
Neurology.
1995;45:1268-1276
218.
Johnson KP, Brooks BR, Cohen JA, et al.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability.
Neurology.
1998;50:701-708 219. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997;244:153-159[CrossRef][Medline] [Order article via Infotrieve].
220.
Edan G, Miller D, Clanet M, et al.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
J Neurol Neurosurg Psychiatry.
1997;62:112-118
221.
Sadovnick AD, Eisen K, Ebers GC, Paty DW.
Cause of death in patients attending multiple sclerosis clinics.
Neurology
1991;41:1193-1196 222. McFarland HF, Stone LA, Calabresi PA, Maloni H, Bash CN, Frank JA. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler. 1996;2:198-205[Medline] [Order article via Infotrieve]. 223. Filippi M, Rovaris M, Comi G. Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment. Ital J Neurol Sci. 1996;17:385-391[CrossRef][Medline] [Order article via Infotrieve].
224.
Confavreux C, Vukusic S, Moreau T, Adeleine P.
Relapses and progression of disability in multiple sclerosis.
N Engl J Med.
2000;343:1430-1438
225.
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L.
Axonal transection in the lesions of multiple sclerosis.
N Engl J Med.
1998;338:278-285
226.
De Stefano N, Matthews PM, Fu L, et al.
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.
Brain.
1998;121:1469-1477
227.
Fu L, Matthews PM, De Stefano N, et al.
Imaging axonal damage of normal-appearing white matter in multiple sclerosis.
Brain.
1998;121:103-113
228.
Ferguson B, Matyszak MK, Esiri MM, Perry VH.
Axonal damage in acute multiple sclerosis lesions.
Brain.
1997;120:393-399 229. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant. 1995;16:1-6[Medline] [Order article via Infotrieve]. 230. Burt RK, Cohen BA, Lobeck LJ, et al. Immune suppressive therapy with autologous hematopoietic stem cell transplantation arrests active CNS inflammation but not axonal atrophy in patients with severe disability and progressive multiple sclerosis [abstract]. Blood. 2001;98:687a.
231.
Mancardi GL, Saccardi R, Filipppi M, et al.
Autologous hempatopoietic stem cell transplantation suppresses gd-enhanced MRI activity in MS.
Neurology.
2001;57:62-68 232. Carreras E, Saiz A, Graus F, et al. Autologous CD34+ selected hematopoietic stem cell transplantation (CD34+/HSCT) for multiple sclerosis: update of a single center experience in 10 patients [abstract]. Biol Blood Marrow Transplant. 2001;7:69. 233. Mandalfino P, Rice G, Smith A, Klein JL, Rystedt L, Ebers GC. Bone marrow transplantation in multiple sclerosis. J Neurol. 2000;247:691-695[CrossRef][Medline] [Order article via Infotrieve].
234.
Jacobs LD, Beck RW, Simon JH, et al.
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
N Engl J Med.
2000;343:898-904 235. Kono DH, Theophilopoulos AN. Genetic susceptibility to spontaneous lupus in mice. In: Theophilopoulos AN, ed. Genes and Genetics of Autoimmunity. Vol 1 Current Directions in Autoimmunity. Basel, Switzerland: Karger; 1999:72-98.
236.
Coutinho A.
An outsider's view on SLE research.
Lupus.
1999;8:171-173 237. Wallace DJ,Hahn BH, eds. Dubois' Lupus Erythematosus. Baltimore, MD: Williams & Wilkins; 1997:1-1227. 238. Lahita RG, ed. Systemic Lupus Erythematosus. San Diego, CA: Academic Press; 1999:1-1003. 239. Hochberg MC. Epidemiology of systemic lupus erythematosus. In: Wallace DJ,Hahn BH, eds. Dubois' Lupus Erythematosus. Baltimore, MD: Williams & Wilkins; 1997:49-69. 240. Alarcon-Segovia D, Alarcon-Riquelme ME. Etiopathogenesis of systemic lupus erythematosus: a tale of three troikas. In: Lahita RG, ed. Systemic Lupus Erythematosus. San Diego, CA: Academic Press; 1999:56-65. 241. Liossis SN, Tsokos GC. Systemic lupus erythematosus. In: Tsokos GC, ed. Principles of Molecular Rheumatology. Totowa, NJ: Humana Press; 2000:311-323.
242.
Old treatment-new treatment [special issue].
Lupus.
2001;10:135-248
243.
Takada K, Illei GC, Boumpas DT.
Cyclophosphamide for the treatment of systemic lupus erythematosus.
Lupus.
2001;10:154-161 244. Treatment-resistant rheumatic disease. Rheum Dis Clin N Am. 1995;21:1-18[Medline] [Order article via Infotrieve].
245.
Marmont AM.
Perspective: immunoablation with stem cell rescue: a possible cure for systemic lupus erythematosus.
Lupus.
1993;2:151-156 246. Musso M, Porretto F, Crescimanno A, Bondi F, Polizzi V, Scalone R. Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell infusion for severe autoimmune diseases. Am J Hematol. 2001;66:75-79[CrossRef][Medline] [Order article via Infotrieve].
247.
Marmont AM.
Eminence-based medicine. Lupus: tinkering with hematopoietic stem cells.
Lupus.
2001;10:1-6 248. Symmons DPM, Coopock JS, Bacon PA, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. QJM. 1988;68:927-937. 249. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35:630-640[Medline] [Order article via Infotrieve]. 250. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988;31:817-825[Medline] [Order article via Infotrieve]. 251. Petri M, Bochemstedt L, Colman J, et al. Serial assessment of glomerular filtration rate in lupus nephropathy. Kidney Int. 1988;34:832-839[Medline] [Order article via Infotrieve]. 252. Gladman DD, Goldsmith CH, Urowitz MB, et al. Crosscultural validation and reliability of three disease activity indices in systemic lupus erythematosus. J Rheum. 1992;19:608-611[Medline] [Order article via Infotrieve]. 253. Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to change of three SLE disease activity indices: international validation. J Rheum. 1994;21:1468-1471[Medline] [Order article via Infotrieve]. 254. Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum. 1997;27:123-140[CrossRef][Medline] [Order article via Infotrieve]. 255. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, et al., eds. Textbook of Rheumatology. 5th ed. Philadelphia, PA: WB Saunders; 1996:851-897. 256. Goronzy JJ, Zettl A, Weyand CM. T cell receptor repertoire in rheumatoid arthritis. Int Rev Immunol. 1998;17:339-363[Medline] [Order article via Infotrieve].
257.
Hall FC, Thomson K, Procter J, McMichael AJ, Wordsworth BP.
TCR beta spectratyping in RA: evidence of clonal expansions in peripheral blood lymphocytes.
Ann Rheum Dis.
1998;57:319-322 258. Lamb JR, Young DB. T cell recognition of stress proteins. A link between infectious and autoimmune disease. Mol Biol Med. 1990;7:311-321[Medline] [Order article via Infotrieve]. 259. He X, Kang AH, Stuart JM. Accumulation of T cells reactive to type II collagen in synovial fluid of patients with rheumatoid arthritis. J Rheumatol. 2000;27:589-593[Medline] [Order article via Infotrieve]. 260. Weinberg JB, Wortham TS, Misukonis MA, Patton KL, Chitneni SR. Synovial mononuclear phagocytes in rheumatoid arthritis and osteoarthritis: quantitative and functional aspects. Immunol Invest. 1993;22:365-374[Medline] [Order article via Infotrieve]. 261. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints: stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest. 1989;83:1267-1276. 262. Muller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol. 1996;149:1607-1615[Abstract]. 263. Kullmann F, Judex M, Neudecker I, et al. Analysis of the p53 tumor suppressor gene in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 1999;42:1594-1600[CrossRef][Medline] [Order article via Infotrieve]. 264. Hollingsworth JW. Non-articular complications of rheumatoid arthritis. Med Times. 1970;98:121-130[Medline] [Order article via Infotrieve]. 265. Hart FD. Rheumatoid arthritis: extra-articular manifestations. II. BMJ. 1970;2:747-752. 266. Callahan LF, Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res. 1995;8:229-241[Medline] [Order article via Infotrieve].
267.
Pincus T, Brooks RH, Callahan LF.
Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures.
Ann Intern Med.
1994;120:26-34 268. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum. 1986;29:706-714[Medline] [Order article via Infotrieve]. 269. Leigh JP, Fries JF. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol. 1991;18:1307-1312[Medline] [Order article via Infotrieve]. 270. Pincus T, Callahan LF, Vaughn WK. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol. 1987;14:240-251[Medline] [Order article via Infotrieve]. 271. Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 1953;249:553-556. 272. Myllykangas-Luosujarvi RA, Aho K, Isomaki HA. Mortality in rheumatoid arthritis. Semin Arthritis Rheum. 1995;25:193-202[CrossRef][Medline] [Order article via Infotrieve]. 273. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomaki H. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol. 1995;13:149-153[Medline] [Order article via Infotrieve]. 274. Vandenbroucke J, Hazevoet HM. Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol. 1984;11:158-161[Medline] [Order article via Infotrieve]. 275. Uddin J, Kraus AS, Kelly HG. Survivorship and death in rheumatoid arthritis. Arthritis Rheum. 1970;13:125-130[Medline] [Order article via Infotrieve].
276.
Klippel JH.
Biologic therapy for rheumatoid arthritis.
N Engl J Med.
2000;343:1640-1641 277. Verburg RJ, Kruize AA, van den Hoogan FHJ, et al. High dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum. 2001;44:754-760[CrossRef][Medline] [Order article via Infotrieve]. 278. Munro R, Madhok R. T-cell-depleted stem-cell transplantation for rheumatoid. Lancet. 1998;352:1628-1629[Medline] [Order article via Infotrieve]. 279. Amett F, Edworthy S, Bloch D, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324[Medline] [Order article via Infotrieve]. 280. Silman AJ, Black CM, Welsh KI. Epidemiology, demographics, genetics. In: Clements P,Furst D, eds. Systemic Sclerosis. Baltimore, MD: Williams & Wilkins; 1996:23-50. 281. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum. 1999;42:2660-2665[CrossRef][Medline] [Order article via Infotrieve]. 282. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum. 1990;33:1256-1263[Medline] [Order article via Infotrieve]. 283. Altman RD, Medsger TA, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991;34:403-413[Medline] [Order article via Infotrieve].
284.
Jacobsen S, Halberg P, Ullman S.
Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma).
Br J Rheumatol.
1998;37:750-755
285.
Bryan C, Howard Y, Brennan P, Black C, Silman A.
Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population.
Br J Rheumatol.
1996;35:1122-1126 286. Abu-Shakra M, Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol. 1995;22:2100-2102[Medline] [Order article via Infotrieve]. 287. Briggs D, Welsh KI. Major histocompatibility complex class II genes and systemic sclerosis. Ann Rheum Dis. 1991;50(suppl 4):862-865.
288.
Hietarinta M, Koskimies S, Lassila O, Soppi E, Toivanen A.
Familial scleroderma: HLA antigens and autoantibodies.
Br J Rheumatol.
1993;32:336-338 289. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999;42:1194-1203[CrossRef][Medline] [Order article via Infotrieve].
290.
van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB.
Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.
Br J Rheumatol.
1996;35:364-372 291. Grassegger A, Schuler G, Hessenberger G, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol. 1998;139:639-648[CrossRef][Medline] [Order article via Infotrieve].
292.
White B, Moore WC, Wigley FM, Xiao HQ, Wise RA.
Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.
Ann Int Med.
2000;132:947-954 293. Norton WL, Nardo JM. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Int Med. 1970;73:317-324. 294. Kahaleh MB. The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy). Clin Exp Rheumatol. 1992;10(suppl 7):51-56. 295. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Int Med. 1981;94:482-484.
296.
Siracusa LD, Sherratt MJ, Peters R, Shuttleworth CA, Jimenez SA.
The Tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils.
J Cell Biol.
1998;140:1159-1166
297.
Siracusa LD, McGrath R, Ma Q, et al.
A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation.
Genome Res.
1996;6:300-313
298.
Gayraud B, Keene DR, Sakai LY, Ramirez F.
New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin 1 mutation in the tight skin mouse.
J Cell Biol.
2000;150:667-680 299. Guldner HH, Szostecki C, Vosberg HP, Lakomek HJ, Penner E, Bautz FA. Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosoma. 1986;94:132-138[CrossRef][Medline] [Order article via Infotrieve].
300.
Maul GG, French BT, van Venrooij WJ, Jimenez SA.
Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase.
Proc Natl Acad Sci U S A.
1986;83:5145-5149 301. Steen VD, Ziegler GL, Rodnan GP, Medsger TA. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984;27:125-131[Medline] [Order article via Infotrieve]. 302. Graham-Brown RA, Sarkany I. Scleroderma-like changes due to chronic graft-versus-host disease. Clin Exp Dermatol. 1983;8:531-538[CrossRef][Medline] [Order article via Infotrieve]. 303. Claman HN. Graft-versus-host disease and animal models for scleroderma. Curr Opin Rheumatol. 1990;2:929-931[Medline] [Order article via Infotrieve]. 304. Bos G, Majoor G, Slaaf D, Reneman R, van Breda Vriesman P. In vivo demonstration of microvascular pathology by intravital microscopy in experimental chronic graft-versus-host disease: analogy with scleroderma. J Rheumatol. 1988;15:1339-1345[Medline] [Order article via Infotrieve]. 305. Nelson JL, Furst DE, Maloney S, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet. 1998;351:559-562[CrossRef][Medline] [Order article via Infotrieve]. 306. Maloney S, Smith A, Furst DE, et al. Microchimerism of maternal origin persists into adult life. J Clin Invest. 1999;104:41-47[Medline] [Order article via Infotrieve]. 307. Shen N, Ffrench P, Guyotat D, et al. Expression of adhesion molecules in endothelial cells during allogeneic bone marrow transplantation. Eur J Haematol. 1994;52:296-301[Medline] [Order article via Infotrieve].
308.
Binks M, Passweg JR, Furst D, et al.
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.
Ann Rheum Dis.
2001;60:577-584 309. LaFace DM, Peck AB. Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes. Diabetes. 1989;38:894-901[Abstract]. 310. Karussis DM, Vourka-Karussis U, Lehmann D, Abramsky O, Ben-Nun A, Slavin S. Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT). Clin Exp Immunol. 1995;100:111-117[Medline] [Order article via Infotrieve]. 311. Kushida T, Inaba M, Takeuchi K, Sugiura K, Ogawa R, Ikehara S. Treatment of intractable autoimmune diseases in MRL/lpr mice using a new strategy for allogeneic bone marrow transplantation. Blood. 2000;5:1862-1868. 312. van Gelder M, Mulder AH, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis with largely MHC-matched allogeneic bone marrow transplantation. Transplantation. 1996;62:810-818[CrossRef][Medline] [Order article via Infotrieve]. 313. El-Badri NS, Wang BY, Steele A, et al. Successful prevention of autoimmune disease by transplantation of adequate number of fully allogeneic hematopoietic stem cells. Transplantation. 2000;70:870-877[CrossRef][Medline] [Order article via Infotrieve]. 314. Kirzner RP, Engelman RW, Mizutani H, Specter S, Good RA. Prevention of coronary vascular disease by transplantation of T-cell-depleted bone marrow and hematopoietic stem cell preparation in autoimmune-prone w/BF(1) mice. Biol Blood Marrow Transplant. 2000;6:513-522[CrossRef][Medline] [Order article via Infotrieve].
315.
Takeuchi K, Inaba M, Miyashima S, Ogawa R, Ikehara S.
A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice.
Blood.
1998;91:4616-4623 316. Li H, Kaufman CL, Ildstad ST. Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice. Surgery. 1995;118:192-198[CrossRef][Medline] [Order article via Infotrieve].
317.
Himeno K, Good RA.
Marrow transplantation from tolerant donors to treat and prevent autoimmune diseases in BXSB mice.
Proc Natl Acad Sci U S A.
1988;85:2235-2239
318.
Yasumizu R, Sugiura K, Iwai H, et al.
Treatment of type 1 diabetes mellitus in non-obese diabetic mice by transplantation of allogeneic bone marrow and pancreatic tissue.
Proc Natl Acad Sci U S A.
1987;84:6555-6557
319.
Ikehara S, Ohtsuki H, Good RA, et al.
Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation.
Proc Natl Acad Sci U S A.
1985;82:7743-7747
320.
Ikehara S, Good RA, Nakamura T, et al.
Rationale for bone marrow transplantation in the treatment of autoimmune diseases.
Proc Natl Acad Sci U S A.
1985;82:2483-2487
321.
Ikehara S, Yasumizu R, Inaba M, et al.
Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation.
Proc Natl Acad Sci U S A.
1989;86:3306-3310 322. Weissman IL. Transfer of tolerance. Transplantation. 1973;15:265-269[CrossRef][Medline] [Order article via Infotrieve]. 323. Sykes M. Hematopoietic cell transplantation for the induction of allo- and xenotolerance. Clin Transplant. 1996;10:357-363[Medline] [Order article via Infotrieve].
324.
Nakamura T, Good RA, Yasumizu R, et al.
Successful liver allografts in mice by combination with allogeneic bone marrow transplantation.
Proc Natl Acad Sci U S A.
1986;83:4529-4532 325. Gandy KL, Weissman IL. Tolerance of allogeneic heart grafts in mice simultaneously reconstituted with purified allogeneic hematopoietic stem cells. Transplantation. 1998;65:295-304[CrossRef][Medline] [Order article via Infotrieve]. 326. Kawaharada N, Shears LL 2nd, Li S, Pham SM. Mixed hematopoietic chimerism prevents allograft vasculopathy. J Heart Lung Transplant. 1999;18:532-541[CrossRef][Medline] [Order article via Infotrieve]. 327. Remuzzi G. Cellular basis of long-term organ transplant acceptance: pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. Am J Kidney Dis. 1998;31:197-212[Medline] [Order article via Infotrieve]. 328. George JF, Sweeney SD, Kirklin JK, Simpson EM, Goldstein DR, Thomas JM. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat Med. 1998;4:333-335[CrossRef][Medline] [Order article via Infotrieve]. 329. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol. 2000;28:853-857[CrossRef][Medline] [Order article via Infotrieve]. 330. Burt RK, Traynor A. Hematopoietic stem cell therapy of autoimmune diseases. Curr Opin Hematol. 1998;5:472-477[Medline] [Order article via Infotrieve]. 331. Weiden PL, Sullivan KM, Fluornoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-1533[Medline] [Order article via Infotrieve].
332.
Horowitz MM, Gale RP, Sondel PM, et al.
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood.
1990;75:555-562 333. Li H, Kaufman CL, Boggs SS, Johnson PC, Patrene KD, Ildstad ST. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J Immunol. 1996;156:380-388[Abstract].
334.
Wang B, Yamamoto Y, El-Badri NS, Good RA.
Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice.
Proc Natl Acad Sci U S A.
1999;96:3012-3016
335.
Wang BY, Cherry, El-Badri NS, Good RA.
Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation.
Proc Natl Acad Sci U S A.
1997;94:12065-12069 336. Delaney CP, Murase N, Chen-Woan M, Fung JJ, Starzl TE, Demetris AJ. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. J Clin Invest. 1996;97:217-225[Medline] [Order article via Infotrieve]. 337. Prigozhina T, Gurevitch O, Slavin S. Non-myeloblative conditioning to induce tolerance after allogeneic bone marrow transplantation in mice. Exp Hematol. 1999;27:1503-1510[CrossRef][Medline] [Order article via Infotrieve]. 338. Weiss L, Slavin S. Prevention and treatment of graft vs host disease by down regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant. 1999;23:1139-1143[CrossRef][Medline] [Order article via Infotrieve]. 339. Yin JA, Jowitt SN. Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant. 1992;9:31-33[Medline] [Order article via Infotrieve]. 340. Cooley HM, Snowden JA, Grigg AP, Wicks IP. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis Rheum. 1997;40:1712-1715. 341. Olalla JI, Ortin M, Hermida G, et al. Disappearance of lupus anticoagulant after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:83-85[CrossRef][Medline] [Order article via Infotrieve]. 342. Adkins DR, Abidi MH, Brown RA, et al. Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy. Bone Marrow Transplant. 2000;26:1239-1241[CrossRef][Medline] [Order article via Infotrieve]. 343. Snowden JA, Kearney P, Kearney A, et al. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum. 1998;41:453-459[CrossRef][Medline] [Order article via Infotrieve]. 344. Baldwin JL, Storb R, Thomas ED, Mannik M. Bone marrow transplantation in patients with gold-induced marrow aplasia. Arthritis Rheum. 1977;20:1043-1048[Medline] [Order article via Infotrieve]. 345. Jacobs P, Vincent MD, Martell RW. Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia. Bone Marrow Transplant. 1986;1:237-239[Medline] [Order article via Infotrieve]. 346. Eedy DJ, Burrows D, Bridges JM, Jones FGC. Clearance of severe psoriasis after allogeneic bone marrow transplantation. BMJ. 1990;300:908. 347. Liu-Yin JA, Jowitt SN. Resolution of immune mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant. 1992;9:31-33. 348. Lowenthal RM, Cohen ML, Atkinson K, Biggs JC. Apparent cure of rheumatoid arthritis following bone marrow transplantation. J Rheumatol. 1993;20:137-140[Medline] [Order article via Infotrieve]. 349. McKendry RJR, Huebsch L, Leclair B. Progression of rheumatoid arthritis following bone marrow transplantation: a case report with a 13-year followup. Arthritis Rheum. 1996;39:1246-1253[Medline] [Order article via Infotrieve]. 350. Vento S, Cainelli F, Renzini C, Ghironzi G, Concia E. Resolution of autoimmune hepatitis after bone marrow transplantation. Lancet. 1996;348:544-545[Medline] [Order article via Infotrieve]. 351. Roychoudhury DF, Linker CA. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant. 1995;16:471-472[Medline] [Order article via Infotrieve]. 352. Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology. 1998;114:433-440[CrossRef][Medline] [Order article via Infotrieve]. 353. Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol. 1997;48(suppl):23-29. 354. De Stefano P, Zecca M, Giorgiani G, Perotti C, Giraldi E, Locatelli F. Resolution of immune haemolytic anaemia with allogeneic bone marrow transplantation after an unsuccessful autograft. Br J Haematol. 1999;106:1063-1064[CrossRef][Medline] [Order article via Infotrieve]. 355. Muller BU, Tichelli A, Passweg JR, Nissen C, Wodnar-Filipowicz A, Gratwohl A. Successful treatment of refractory acquired pure red cell aplasia (PRCA) by allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:1205-1207[CrossRef][Medline] [Order article via Infotrieve]. 356. Raetz E, Beatty PG, Adams RH. Treatment of severe Evans syndrome with an allogeneic cord blood transplant. Bone Marrow Transplant. 1997;20:427-429[CrossRef][Medline] [Order article via Infotrieve]. 357. Oyama Y, Papadopoulos EB, Miranda M, Traynor A, Burt RK. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant. 2001;28:903-905[CrossRef][Medline] [Order article via Infotrieve]. 358. Nash RA, Dansey R, Storek J, et al. Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases [abstract]. Blood. 2000;96(suppl):406a.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  C. E. B. Couri, M. C. B. Oliveira, A. B. P. L. Stracieri, D. A. Moraes, F. Pieroni, G. M. N. Barros, M. I. A. Madeira, K. C. R. Malmegrim, M. C. Foss-Freitas, B. P. Simoes, et al. C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus JAMA, April 15, 2009; 301(15): 1573 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Alexander, A. Thiel, O. Rosen, G. Massenkeil, A. Sattler, S. Kohler, H. Mei, H. Radtke, E. Gromnica-Ihle, G.-R. Burmester, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system Blood, January 1, 2009; 113(1): 214 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Voltarelli, C. E. B. Couri, A. B. P. L. Stracieri, M. C. Oliveira, D. A. Moraes, F. Pieroni, M. Coutinho, K. C. R. Malmegrim, M. C. Foss-Freitas, B. P. Simoes, et al. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus JAMA, April 11, 2007; 297(14): 1568 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Skyler Cellular Therapy for Type 1 Diabetes: Has the Time Come? JAMA, April 11, 2007; 297(14): 1599 - 1600. [Full Text] [PDF]
|
|
|
|
|
|
R. K. Burt, A. Traynor, L. Statkute, W. G. Barr, R. Rosa, J. Schroeder, L. Verda, N. Krosnjar, K. Quigley, K. Yaung, et al. Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus JAMA, February 1, 2006; 295(5): 527 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Beilhack, R. R. Landa, M. A. Masek, and J. A. Shizuru Prevention of Type 1 Diabetes with Major Histocompatibility Complex-Compatible and Nonmarrow Ablative Hematopoietic Stem Cell Transplants Diabetes, June 1, 2005; 54(6): 1770 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Burt From animals to clinic: nonmyeloablative conditioning and allogeneic bone marrow transplantation in autoimmune disease Blood, April 1, 2005; 105(7): 2623 - 2624. [Full Text] [PDF]
|
|
|
|
|
|
R. Flierman, H. J. Witteveen, E. I. H. van der Voort, T. W. J. Huizinga, R. R. P. de Vries, W. E. Fibbe, R. E. M. Toes, and J. M. van Laar Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation Blood, April 1, 2005; 105(7): 2991 - 2994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Muraro, D. C. Douek, A. Packer, K. Chung, F. J. Guenaga, R. Cassiani-Ingoni, C. Campbell, S. Memon, J. W. Nagle, F. T. Hakim, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients J. Exp. Med., March 7, 2005; 201(5): 805 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Talaulikar, K E Tymms, I Prosser, and R Smith Autologous peripheral blood stem cell transplantation with in vivo T-cell depletion for life threatening refractory systemic lupus erythematosus Lupus, February 1, 2005; 14(2): 159 - 163. [Abstract] [PDF]
|
|
|
|
|
|
H. Kared, A. Masson, H. Adle-Biassette, J.-F. Bach, L. Chatenoud, and F. Zavala Treatment With Granulocyte Colony-Stimulating Factor Prevents Diabetes in NOD Mice by Recruiting Plasmacytoid Dendritic Cells and Functional CD4+CD25+ Regulatory T-Cells Diabetes, January 1, 2005; 54(1): 78 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Voltarelli, M. C. B. Oliveira, A. B. P. L. Stracieri, D. F. Godoi, D. A. Moraes, M. A. Coutinho, K. C. R. Malmegrim, and A. C. Santos Haematopoietic stem cell transplantation for refractory Takayasu's arteritis Rheumatology, October 1, 2004; 43(10): 1308 - 1309. [Full Text] [PDF]
|
|
|
|
 |
|
 D Farge, J Passweg, J M van Laar, Z Marjanovic, C Besenthal, J Finke, H H Peter, F C Breedveld, W E Fibbe, C Black, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry Ann Rheum Dis, August 1, 2004; 63(8): 974 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jayne, J. Passweg, A. Marmont, D. Farge, X. Zhao, R. Arnold, F. Hiepe, I. Lisukov, M. Musso, J. Ou-Yang, et al. Autologous stem cell transplantation for systemic lupus erythematosus Lupus, March 1, 2004; 13(3): 168 - 176. [Abstract] [PDF]
|
|
|
|
|
|
I A Lisukov, S A Sizikova, A D Kulagin, I V Kruchkova, A V Gilevich, L P Konenkova, E V Zonova, E R Chernykh, O Y Leplina, T N Sentyakova, et al. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus Lupus, February 1, 2004; 13(2): 89 - 94. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Palmarini, M. Mura, and T. E. Spencer Endogenous betaretroviruses of sheep: teaching new lessons in retroviral interference and adaptation J. Gen. Virol., January 1, 2004; 85(1): 1 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Murphy, M. Biondo, B.-H. Toh, and F. Alderuccio Tolerance established in autoimmune disease by mating or bone marrow transplantation that target autoantigen to thymus Int. Immunol., January 1, 2003; 15(2): 269 - 277. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Autoimmunity: definition
portion of a TCR.
Superantigen binding occurs outside the MHC peptide-binding groove and
outside the TCR CDR3 antigen-specific recognition site. Activation by
superantigen results in overexpansion and/or deletion of entire
V
an infectious disease?
Ann Allergy.
1988;60:377-378